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ABSTRACT 
DEVELOPMENT AND CHARACTERIZATION OF AN IN-
HOUSE CUSTOM BIOREACTOR FOR THE CULTIVATION 
OF A TISSUE ENGINEERED BLOOD-BRAIN BARRIER 	  
Amin Mirzaaghaeian 	  
The development of treatments for neurological disorders such as Alzheimer’s 
and Parkinson’s disease begins by understanding what these diseases affect and the 
consequences of further manifestation. One particular region where these diseases can 
produce substantial problems is the blood-brain barrier (BBB). The BBB is the selective 
diffusion barrier between the circulating blood and the brain. The barrier’s main function 
is to maintain CNS homeostasis and protect the brain from the extracellular environment. 
The progression of BBB research has advanced to the point where many have modeled 
the BBB in vitro with aims of further characterizing and testing the barrier. Particularly, 
the pharmaceutical industry has gained interest in this field of research to improve drug 
development and obtain novel treatments for patients so the need for an improved model 
of the BBB is pertinent in their discovery. In the Cal Poly Tissue Engineering lab, an in 
vitro tissue engineered BBB system has previously been obtained and characterized for 
the initial investigation of the barrier and its components. However, certain limitations 
existed with use of the commercial system. Therefore, the focus of this thesis was to 
improve upon the capabilities and limitations of this commercialized system to allow 
further expansion of BBB research. The work performed was based on three aims: first to 
design and develop an in-house bioreactor system that could be used to cultivate the 
BBB; second, to characterize flow and functional capabilities of the bioreactor; third, to 
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develop protocols for the overall use of the bioreactor, to ultimately allow co-cultures of 
BAEC and C6 glioma cells, and further the progression toward creating an in vitro model 
of the BBB.  
The work of this thesis demonstrates development of an in-house custom 
bioreactor system that can successfully culture cells. Results showed that the system was 
reusable, could be sterilized and monitored, was easily used by students trained in the 
laboratory, and allowed non-destructive scaffold extraction. This thesis also discusses the 
next set of experiments that will lead to an in vitro model of the BBB.  
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Chapter 1: Introduction 
1.1 The Blood-Brain Barrier 	  
Over a century has passed since the term “blood-brain barrier” was first used [1], and 
today numerous studies can confidently describe the major functions of the blood-brain 
barrier (BBB).  The barrier’s main function is to maintain CNS homeostasis by providing 
a perpetual supply of nutrients through specified transport mechanisms, regulating 
inflammatory cells in response to changes in the local environment, and protecting the 
brain from the extracellular environment [2,3,4]. Characterization of these functions 
became possible from understanding the components of the BBB including endothelial 
cells, pericytes, basement membrane, and neural cells (Fig. 1). 
	  
Figure 1: Diagram of the associated components of the BBB, illustrating the location and 
orientation of each component relative to blood flow [4]. 
1.2 Components of the Barrier 
The permeability of the barrier is dependent on the presence of the brain 
microvascular endothelial cells (BMVEC) [4]. However, the integrity of the barrier relies 
on the complementary components of the neurovascular unit (NVU) [5]. The NVU 
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consists of BMVECs, a basement membrane, pericytes, astrocytes, and microglia; each of 
these will be explained in the following section (Fig. 2) [1]. Each component plays a 
contributing role in either the integrity of the barrier’s permeability or BMVEC 
phenotype expression.  
 
	  
Figure 2: Animation of the neurovascular unit comprised of endothelial cells, a basement 
membrane, pericytes, astrocyte, microglia, and neurons [1]. 
1.2.1 Brain Microvascular Endothelial Cells 
BMVECs represent the anatomic basis and the primary component of the BBB 
[6,7], and are the only component of the NVU that contacts the circulating blood. The 
endothelial cells (ECs) mediate metabolism and selective transport of substances from 
blood to the brain or vice versa from the parenchyma into the circulation. The EC’s 
ability to communicate with the surrounding components results in maintenance and 
amplification of proper brain homeostasis [8].  BMVECs differ from other vascular ECs 
in that they display a higher expression of certain characteristics by being a part of the 
BBB. Specifically, BMVECs are fifty to one hundred times tighter compared to the rest 
of the peripheral system, due to the formation of tight junctions (TJs) between adjacent 
ECs, causing inhibition of certain hydrophilic solutes [9]. The BMVEC lining is 
The BBB is present in all brain regions, except in those
regulating autonomic nervous systemand endocrine glands of
the body, where blood vessels permit diffusion of blood-borne
molecules across the vessel wall (Ballabh et al., 2004).
BBB's specific structural and biochemical properties arise
from existent layers between the blood and the brain and from
interactions between a large variety of cell types (Khan, 2005;
Hawkins et al., 2006),whichwill be explored in thenext sections.
2. Neurovascular unit
In the developing brain, capillaries are differentiated and
matured into the BBB (Lee et al., 2006). Only capillary vessels
have complete BBB properties, since leakiness increases as the
vessel diameter increases (Marchi et al., 2004; Hawkins and
Davis, 2005).
Although BBB permeability itself is controlled by the
biochemical properties of brain microvascular endothelial
cells (BMVEC) (Pardridge, 1999), brain microvascular biology
results overall from interactions of these cells with the
basement membrane and neighboring glial cells (Kaur and
Ling, 2008), such as microglia and astrocytes, as well as
neurons and perivascular pericytes (Wolburg and Lippoldt,
2002; Zlokovic, 2008; Zozulya et al., 2008). Altogether these
constitute the neurovascular unit (NVU) (Persidsky et al.,
2006a; Choi and Kim, 2008) (Fig. 2), essential for both health
and function of the CNS (Hawkins and Davis, 2005).
2.1. Basement membrane
The basement membrane is an essential part of the BBB. It
surrounds BMVEC and engulfs pericytes, anchoring the cells in
place and establishing the connection with the surrounding
brain resident cells (Carvey et al., 2009). BMVEC, pericytes and
astrocytes all cooperate to generate and maintain the base-
ment membrane that is constituted by 3 apposed laminas,
composed of different extracellular matrix classes of mole-
cules (Persidsky et al., 2006a; Weiss et al., 2009). These are
structural proteins (collagen and elastin), specialized proteins
(fibronectin and laminin) and proteoglycans (Adibhatla and
Hatcher, 2008; Wolburg et al., 2009). The basement membrane
also includes matrix adhesion receptors, known as cell
adhesion molecules (CAM), as well as signaling proteins,
which form an extensive and complex matrix (Carvey et al.,
2009). These molecules are expressed in the vascular cells,
neurons and supporting glial cells and are essential for main-
tenance of the BBB. Disruption of the basementmembrane can
lead to alterations in the cytoskeleton of BMVEC, which in turn
affects tight junctions (TJ) proteins and barrier integrity.Matrix
metalloproteinases (MMP) are known to digest the baseme t
membrane, which leads to reduced anchoring of brain EC and
matrix–EC signaling that affects TJ integrity and impairs the
barrier integrity (Carvey et al., 2009). Accordingly, disruption
of extracellular matrix has been strongly associated with in-
cre sed BBB permeability in several pathological c nditions
(Hawkins and Davis, 2005; Carvey et al., 2009; Zlokovic, 2008).
2.2. Neurons
Little is known about the developmental role that neurons
have on the BBB phenotype. However, there is some evidence
that neurons can regulate the function of blood vessels in
response tometabolic requirements by inducing expression of
enzymes unique for BMVEC (Persidsky et al., 2006a). Also,
BMVEC and astrocytic processes are directly innervated by
noradrenergic, serotonergic, cholinergic, and GABA-ergic neu-
rons, among others (Hawkins and Davis, 2005). Moreover,
mature endothelium has a reciprocal function in inducing a
stable brain microenvironment that enables proper neuronal
activity (Choi and Kim, 2008).
2.3. Microglia
Microglia play a very important role in immune responses of
the CNS, surveying local microenvironment and changing the
phenotype in response to homeostatic disturbance of the CNS.
In fact, these cells present themselves in two forms: resting
and activatedmicroglia. When resting, cells have small bodies
and long, thin processes; in contrast, activated microglia
assume a phagocytic morphology by shifting from long to
short processes (Zlokovic, 2008). In accordance with the
macrophage population in other organs, these cells have
Fig. 1 – Injected horseradish peroxidase diffuses through
brain vasculature but does not pass through endothelial cells
to brain parenchyma. Designed based on original
observations of Reese and Karnovsky (1967).
Fig. 2 – Schematic overview of the neurovascular unit
composed of endothelial cells, basement membrane,
astrocytes and microglia, neurons and pericytes. Adapted
from Abbott et al. (2006).
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comprised of junctional complexes including TJs and adherens junction proteins (AJs) 
that remove gaps between cells preventing free diffusion of substances from the 
circulation [10,11].  The overall structure of BMVECs differs from ECs of the peripheral 
capillaries, as they are absent of fenestrae, perform minimal pinocytosis, and are 
surrounded by a uniform basement membrane [12,13]. The brain endothelium also 
contains a higher number of mitochondria, allowing increased energy potential to 
perform selective transport into and out of the brain [4,13]. Transmembrane proteins from 
the cellular adhesion molecule family including selectins, immunoglobulins, and 
integrins, participate in intercellular adhesion and focal adhesion to the basement 
membrane [14,15,16]. 
1.2.2 Basement Membrane 
The basement membrane maintains a connection between the surrounding 
components and BMVECs by stabilizing the ECs and surrounding pericytes [17]. The 
membrane is composed of structural proteins including collagen and elastin, specialized 
proteins such as fibronectin and laminin, and proteoglycans [18, 15].  Cellular adhesion 
molecules seen in BMVECs have additional signaling proteins and are pertinent to the 
maintenance of the BBB [17]. A study performed by Carvey et al. investigated several 
dysfunctions including damage to the basement membrane and its affect on BMVEC 
cytoskeleton. The researchers showed that damage to the basement membrane lead to a 
decrease in tight junction efficiency and barrier performance [17].  
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1.2.3 Pericytes  
Sharing the basement membrane, but located on endothelial cells, lay pericytes 
that are not just specific to BMVECs, but can be found in other capillaries and post-
capillary venules. Pericytes are also known as vascular smooth muscle cells or 
myofibroblasts, and cover 22-32% of capillaries [19].  However, pericytes in the cerebral 
region express a higher degree of coverage based on the tightness of the intercellular 
junctions [20]. Communication between pericytes and ECs exists due to the presence of 
gap junctions, TJs, adhesion plaques, and soluble factors [21, 22]. Claims have been 
made indicating that pericytes have influential factors on ECs through their ability to 
communicate. Persidsky et al. illustrated the ability for pericytes to modulate BMVEC 
migration, proliferation, and differentiation, all of which can increase the integrity of the 
BBB [4].  Pericytes can also affect the permeability of the BBB due to environmental 
changes.  During hypoxia or traumatic brain injuries, pericytes have been seen to migrate 
away from the BMVECs, increasing permeability of the barrier [23].  
1.2.4 Glial Cells 
Glial cells are the remaining components of the NVU that contribute to the 
function and properties of the BBB [1]. Glial cells include astrocytes and microglia cells. 
Astrocytes have been seen to restore the barrier’s function and properties once added in 
co-culture with BMVECs [24]. Through this observation, astrocytes can be seen to 
modulate neurovascular structure and integrity [25]. Microglia contribute to the immune 
response of the CNS, altering their phenotype in response to changes in homeostasis. 
Choi et al. hypothesized that as microglia interact with BMVECs, the presence of the 
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glial cells may influence the properties of the BBB [26]. Unfortunately, the exact 
mechanisms of microglia associated with the BBB have not been well characterized [26].  
1.3 The Importance of Modeling the BBB 
 The most important aspect of the BBB, the selective permeability, has been the 
most referenced characteristic when investigating the overall properties, pathologic 
effects, or pharmaceutical potential of the barrier [27,28,29]. In terms of neurological 
disorders, it is thought that dysfunction of the BBB could be involved in early disease 
progression [11]. In Parkinson’s and Alzheimer’s, it is thought that the integrity of the 
BBB declines, resulting in decreased extraction of harmful toxins [10]. During Acquired 
Immune Deficiency Syndrome (AIDS) related dementia, there is an increase in leukocyte 
transport across the barrier [10]. Lastly, a study focused on patients diagnosed with 
epilepsy indicated that an increase in barrier permeability my lead to further progression 
of the disorder [30].   
Modeling the BBB can improve not only the understanding of the progression of 
certain pathologies, but also its progression in the pharmaceutical industry. High 
throughput screening (HTS) accelerates the assessment of the toxic effects of millions of 
compounds to determine which would be good candidates for further investigation [31]. 
Permeability experiments evaluate the transport of drug candidates to the brain and their 
success is necessary for drug companies to progress further through drug development 
[32].  However, as HTS and permeability testing regimes serve as a standard approach for 
drug development, there is a need to improve the models of the BBB to increase the 
efficiency for pharmaceutical companies to create effective therapies.  
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As pharmaceutical companies progress from identification and validation of a test 
target to compound development, they face the challenge of whether to continue the 
development of a new drug [32]. After undergoing HTS, researchers have indicated that 
98% of early drug compounds fail to penetrate the BBB [32]. Failure to penetrate the 
barrier results in additional drug development, requiring additional time and money. This 
scenario described throughout literature and industry, reinforcing the need for more 
efficient models of the BBB whether it is in vivo, ex vivo, in vitro, in silico, or a 
combination of several or all of these [33].  
1.4 Approaches to Modeling the Blood-Brain Barrier 
1.4.1 In Vivo Models 
In vivo models consist of intact living specimen, rather than a section of or a dead 
specimen. In vivo studies are known to be the most reliable due to the their ability to 
represent the brain’s complex microenvironment and the advantage that the specimen’s 
overall systemic effects can be taken into consideration [34,35]. Studies using in vivo 
approaches are conducted on both healthy and diseased models [33,34]. Analyzing 
permeability of the barrier can be performed using intravenous administration [33]. 
Different methods of intravenous administration have been developed including brain 
perfusion, microdialysis, and positron emission tomography [36,37].  
Brain perfusion involves retrograde catheterization and ligation of the external 
and internal carotid arteries [36]. Permeability is quantified by looking at the uptake of 
the functional tissue of the brain. Brain perfusion however, is also known to be a more 
difficult procedure. A more novel approach, microdialysis, is being applied to measure 
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influx and efflux measurements [37]. In this method, a probe is inserted into the brain to 
measure the extracellular fluid, which in animals can be sampled repeatedly or 
continuously. The invasiveness of microdialysis does become an issue however. 
Subsequent probe calibrations and reentry disrupt the tissue and cause variable data 
[36,37].  
Positron emission tomography (PET) has been implemented in in vivo studies for 
its non-invasive methods, and can be applicable to humans.  PET uses an intravenous 
injection of a radiotracer that can be viewed under a positron-emitting scanner [38,36]. 
What is unique about PET is the ability to assess permeability of the barrier and drug 
distribution in specific regions of the brain. The limitations of PET stems from its low 
resolution between injected substances and metabolites, and high costs associated with its 
instrumentation [38]. 
In vivo BBB studies have progressed the research of many different fields 
including brain metabolism, disruption, transport, disease progression, and drug 
biodistribution. In vivo models require live animals that raise the ethical dilemmas of 
animal testing. These models are costly to obtain and also to properly house, feed, and 
dispose of the animals after experiments have been conducted [38]. Therefore, in vivo 
results are also not always translatable to humans [39,40].   
1.4.2 In Situ Model 
In situ modeling focuses on studying samples while they are in their natural 
environment. In situ approaches also investigate healthy and diseased models [39]. In situ 
BBB experiments typically involve rats or porcine models [41,42]. A model known as 
single pass injection involves the injection of a single bolus of radiolabeled compounds 
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into the carotid artery and allows for passage into the cerebral capillaries [40]. This single 
pass injection technique, or Brain Uptake Index (BUI), involves an injection of 
radiolabeled test and reference compounds to analyze composition modifications of the 
injected substance including osmotic pressure, pH, and protein binding [36]. Single pass 
injections are limited in time from when the injected bolus travels through the cerebral 
capillaries and is subsequently lost to the systemic system in 5-15 seconds [38]. This 
method is also known to exclude systemic metabolism [37]. 
1.4.3 Ex Vivo Models 
 Ex vivo models involve experimentation on tissue in an artificial environment 
outside the organism. Blood-brain barrier ex vivo methodologies involve using living 
tissue outside of the specimen, while maintaining the environment that the tissue 
originates from. Ex vivo studies present the ability to study structure and function of the 
barrier, along with the overall environment that the brain is subjected to. Samples taken 
from the brain vary between acute and organotypic culture [44]. Acute studies allow for 
short-term (within hours) experiments [44] while oraganotypic slices involve continuing 
cultures in a bench top model to keep the samples alive, allowing for longer-duration 
experiments [45]. Both methods provide insight into the characteristics and modulation of 
molecular pathways, screening of therapeutic molecules, and discovery of new genes 
[44,45].  
One of the more favorable characteristics of ex vivo BBB models is the ability to only 
utilize a sample of the specimen without the wasting of resources seen in in vivo methods 
[45]. In efforts to not exclude the study on humans, ex vivo studies can be performed 
post-mortem, allowing extraction of the brain tissue during autopsy, greatly increasing 
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the knowledge of human brain tissue [46]. However, the quality of human brain tissue, 
key to the validity of the studies, is greatly affected by degradation and storage 
temperature [46]. The degradation of certain components such as structure and proteins 
of post mortem specimens raise doubt whether or not conclusive results can be accepted 
by researchers in the field [47].  
1.4.4 In silico Models 
An in silico model typically refers to computer aided models. In silico models are 
typically predictive models based on in vivo experimental data [48]. These computational 
models provide a cheaper less restricted methodology when compared to in vivo and ex 
vivo approaches. There are different computational approaches to assess either 
permeability or pharmacokinetic parameters for BBB research [49,50,51]. The latter uses 
Quantitative Structure Activity Relationship (QSAR) approaches, which look at brain and 
blood partitioning at steady state described as Log BB  [50]. Log BB is described as the 
ratio of drug concentration in blood and brain at steady state [49].  A study performed by 
Chen et al. utilized an artificial neural network for predicting permeability of the BBB 
[52]. Their investigation involved eight computational inputs of chemical and molecular 
components including, a multidrug resistance protein (P-gP), transporter probability, 
molar refraction, and plasma protein-binding ratio to achieve an output of Log BB. Log 
BB has drawbacks including the requirement to measure at steady state, altering the 
estimate of brain uptake [52]. In silico models deviate from conventional physical models 
as they are based on computational models. Due to these limitations, any molecule 
confirmed by the model has the potential to lead to false results. 
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1.4.5 In vitro Models 
 In vitro studies permit the evaluation of both animal and human cells in a simpler, 
reproducible, and scalable manner. Interest in in vitro models has increased due to the 
capabilities for predicting penetration of novel drug therapies, evaluating dysfunction of 
the barrier due to progression of various neuropathologies, and pre-screening and 
optimizing new therapies [43]. In terms of retrieving information, in vitro models present 
the ability to test for multiple variables at the same time with a large range of cell types.  
For all types of in vitro models, each must be validated based on certain 
characteristics seen in vivo including tight junctions between endothelial cells, low polar 
molecule permeability, selective permeability based on composition, asymmetric 
permeability to ions, or expression of active extrusion proteins [43]. Above all, there is a 
desire for in vitro models to have straightforward culture protocols and for results to be 
reproducible.  
Culture methods vary between static and dynamic in vitro systems both of which 
provide insight to BBB expression and capabilities [53]. Static monodimensional 
transwell models utilize BMVECs derived from various animal and human sources, 
attempting to show phenotypic characteristics seen in vivo [54]. Transwell models consist 
of inserts that provide compartments that are separated between permeable membranes. 
Cells are cultured on permeable membranes and in growth media designed for the cell 
types used [54]. Isolation of such cells is seen to be the more challenging aspect of the 
method as BMVECs are harvested from brain microvessels by mechanical and enzymatic 
means including homogenization, filtration, sieving, centrifugation, or collagenase [53]. 
Isolation of microvessels translates to disassociation from other cell types of the NVU, 
and loss of BBB phenotype. Consequences of such isolation lead to lack of expression of 
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specific transporters, decrease in TJs, and loss of polarity of the luminal and abluminal 
membranes. As transwell models do not separate between luminal and abluminal 
membranes, the exposure of the same media to both sides may affect the structure of the 
cultured BBB and its characteristics [53].   
Co-cultures of the barrier serve to introduce other cell types of the NVU, such as 
glial cells, to increase in vivo representation, expression of certain endothelial markers, 
trans-endothelial electrical resistance (TEER), and transport related processes [53]. TEER 
is a measurement used to indicate the formation of tight junctions in vitro [54]. Recent 
work by Hatherell et al., focused on using cultures with three associated cell types to 
investigate increases in TJs in human cerebral microvascular endothelial cells under the 
assessment of TEER (Fig. 3) [55].  
Although static culture methods such as transwell inserts have the potential to 
introduce more BBB components, these models still lack the interaction of blood and 
dynamic flow characteristics that may also enhance the integrity of the BBB.  
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Figure 3: Schematic of work performed by Hatherell et al., evaluated three static culture 
models using TEER to assess tight junction resistance [55]. 
 
 Dynamic culture methods utilize the characteristic of flow to model the 
mechanical stimuli found in capillaries with the goal of recapitulating the brain’s 
microvasculature environment. The paradigm of such an apparatus typically involves the 
interaction of ECs intraluminally and a component of the NVU extraluminally in a 
hollow fiber polymer scaffold either made up of poly(lactic-co-glycolic acid) (PLGA) or 
polypropylene, among others [53]. Dynamic in vitro models of the BBB (DIV-BBB) aim 
to mimic the brain microvasculature, producing quasi-physiological conditions for culture 
of human or non-human BMVECs and other NVU cell types [56].  
The potential of dynamic culture methods is not limited to implementation of 
hemodynamic characteristics. Introduction of a co-culture of cells is also possible, which 
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allows better expression of BBB characteristics including ion channels, glucose 
transporters, and enhanced restrictive permeability through paracellular pathways [57] 
(Fig. 4).  
	  
Figure 4: Schematic of one dynamic culture method utilizing a bioreactor with a media 
reservoir, pump, and gas exchanger [56]. 
 
One of the earlier models of a hollow fiber apparatus, developed by Cellco Inc., 
provided artificial capillaries made from polypropylene sealed in a chamber that was 
connected by gas permeable tubing [53] (Fig. 5).  
	  
Figure 5: Cellco Inc. hollow fiber bioreactor equipped with polypropylene artificial 
capillaries coated with ProNectinTM F [53]. 	  
Spectrum Labs then refined this particular design and improved upon scale and cell 
integration. Researchers who have focused on dynamic in vitro models, have often used 
as facilitative glucose transporter type-1 (GluT-1) and MDR 
proteins (eg, P-gp)) and tight junctions, and has helped to 
produce a phenotype which mimics the in vivo phenotype 
more closely. Co-culturing specifically with astrocytes also 
provides an increased trans-endothelial electrical resistance 
(TEER) across the formed barrier, which is increased on 
addition of dexamethasone, or the more recently discovered 
L-α-glycero-phospho-D-myo-inositol (GPI) [31••]. The  
co-culture can be established to enable cell-cell contact 
through astrocytic end-feet by seeding astrocytes and ECs 
on either side of the porous support, or can be arranged 
without any contact by seeding the astrocytes at the bottom 
of the well and the ECs on the porous support. This type of 
model is useful for studying the functionality of the BBB as 
well as transport-related processes and interactions between 
ECs and glia [32•]. This is extremely important since the 
nature and significance of these interactions are still poorly 
understood.  
 
The main advantage of the bidimensional model, compared 
with the monodimensional, is the establishment of 
conditions that mimic more closely the in vivo situation. 
Under these co-culture conditions, ECs retain some of the in 
vivo BBB characteristics, including initiated tight junctions, 
higher TEER values and decreased permeability for 
hydrophilic molecules such as sucrose or inulin. Recent 
studies have provided evidence that the use of conditionally 
immortalized brain capillary EC lines, derived from 
transgenic animals, in co-culture with pericyte and/or 
astrocyte cell lines, can lead to the establishment of a BBB 
model capable of retaining the in vivo transport rate of 
several compounds and various forms of gene expression 
[33]. However, bidimensional modeling still ignores the 
presence of intraluminal blood cells and blood flow, lacking 
the presence of shear stress, which has been demonstrated to 
determine further differentiation of ECs and to play a crucial 
role in the cerebrovascular system promoting the 
differentiation and maintenance of the BBB phenotype 
[34••,35•]. The exposure of the apical membrane to shear 
stress is vital to promote growth inhibition and 
differentiation of ECs and it also serves to induce metabolic 
changes which limit the oxygen and substrate consumption 
of such cells and allow the trafficking of metabolic fuels to 
the brain. Thus, reproducible TEER values in the 
bidimensional model are still low compared to physiological 
values, which affects the overall permeability to hydrophilic 
substances. 
Tridimensional dynamic models of the BBB 
(flow-based) 
Cell culture on hollow fibers has been extensively exploited 
for the mass production of rare cell types, antibodies and, 
more recently, for the modeling of organ-like structures such 
as the BBB. The first DIV-BBB consisting of hollow fibers, 
resulted from the modification of a cell culture system used 
for expansion of hybridoma cells. This newly developed in 
vitro system allows quasi-physiological experimental 
conditions for culturing ECs and astrocytes in a capillary-
like structure and is able to functionally and anatomically 
mimic the brain microvasculature. This apparatus is 
characterized by a pronectin-coated polypropylene  
hollow-fiber structure that enables co-culturing of ECs 
(intraluminally) with glia (extraluminally). The entire 
system is connected to a media reservoir via gas-permeable 
silicon tubes that allow for the exchange of O2 and CO2. A 
servo-controlled variable-speed pulsatile ump generates 
flow from the media source through the capillary bundle 
and back to the media. One-way valves positioned on either 
side of the pump ensure unidirectional flow (Figure 2). The 
pumping mechanism is capable of generating flow levels of
Figure 2. A tridimensional in vitro model of the BBB.  
EC loading port
Glial cell loading port
CO2/O2
Pump
Flow
Media 
reservoir
 
 
ECs are seeded intraluminally in a fibronectin-coated hollow fiber, while astrocytes are cultured extraluminally. The entire system is 
connected to a media reservoir through gas-per eable silicon tubes to allow the exchange of O2 and CO2. A variable-speed pulsatile pu p 
generates flow from the media source through the capillary bundle and back. One-way valves positioned on either side of the pump ensure 
unidirectional flow. 
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the CellMax Duo system from Spectrum Labs to investigate the BBB [53,57,58,59]. The 
Spectrum system contains a perfusion pump that produces flow to a plastic bioreactor 
chamber containing fifty polypropylene hollow fibers [57]. Gas exchange occurs through 
the use of gas permeable silicone tubing [57]. Once flow passes through the outlet of the 
bioreactor, fluid reaches the media reservoir only to be pumped back into the system [57]. 
However, researchers have described the limitations of the system to include inability to 
observe cells, non-reusability, and compatibility issues with tissue slice preparation [58]. 
To advance through these limitations researchers have created their own custom 
bioreactor to proceed forward in BBB research (Fig. 6) [57,58].	  
	  
Figure 6: Custom bioreactor developed by Cucullo et al., after facing limitations with the 
CellMax system [58]. 
 
L. Cucullo et al. / Brain Research 951 (2002) 243–254 249
Fig. 3. Assembly properties and recyclable design of the NDIV-BBB.
3 .3. Flow and pressure profiles in the NDIV-BBB the flow pattern consisted of a complex waveform and that
a substantial drop in pressure occurred at the end of the
In previous papers, we and others have described the capillaries as expected in vivo. Details on this procedure
effects of flow on endothelial cell differentiation and comparable experiments carried out on the DIV-BBB
[17,16,7,15,6,8,20,26,42]. It is recognized, however, that (old model) are available elsewhere [16,15].
different flow (shear) patterns influence endothelial cell
physiology. We have thus investigated the profiles of
pressure (pre- and post-hollow fibers) of the pulsatile flow 4 . Discussion
provided by the QuadMax apparatus. The pulsation fre-
quency used was 100 cycles per minute. Note (Fig. 7) that The main goal of the present study was to develop and
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Cucullo et al. performed a study that evaluated the bioreactor shown in Figure 6 
where certain design requirements were implemented and tested including that the system 
be reusable and allow for fiber extractions and tissue preparations [53,58]. Although 
different in design, the new bioreactor utilized the same methods to establish flow seen in 
the CellMax system. The design of this bioreactor addressed the limitation of single time-
point evaluations seen in the CellMax system by the use of a removable window [58]. 
This resulted in sequential removal of the artificial capillaries without affecting the 
remaining fibers that were not intended for analysis [58]. These researchers were able to 
develop a model of the BBB to characterize co-cultures of endothelial and glial cells [60]. 
   
1.5 Bridging the Gap Between In vivo and In vitro Models 
When comparing all of the available models of the BBB, the capabilities of the 
most translatable method, in vivo, and most scalable, in vitro, may be combined to 
produce an improved model of the BBB. Taking the information gathered from in vivo, 
the BBB can be reverse-engineered in vitro. With a focus on dynamic in vitro models, 
there is the potential to introduce multiple cell types of the NVU and hemodynamic 
forces to enhance the characteristics seen in the native BBB. This could also produce a 
cost effective model and allow for accelerated results that can be directly applicable to 
humans. Researchers in the field have been progressing toward the development of more 
robust models of the barrier for toxicological screening, drug permeability, and general 
characterization. Dehouck et al. conducted a study evaluating the correlation between in 
vitro and in vivo models [61]. Dehouck used an in vivo intracarotid injection model to 
compare drug concentration to an in vitro co-culture BBB model utilizing BMVEC and 
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astrocytes and showed a strong correlation between the drug concentrations for the two 
models [61]. This study suggests that in vitro models can yield appropriate results 
compared to in vivo to further develop a BBB.  
1.6 Academia’s Contribution 
 Currently, the Tissue Engineering Laboratory directed by Dr. Kristen Cardinal at 
California Polytechnic State University, San Luis Obispo performs research in the use of 
blood vessel mimics. Using various scaffold types including expanded 
polytetrafluoroethylene (ePTFE) and PLGA, students apply cell culture methods of 
sodding cells into the scaffolds to create tissue engineered blood vessel mimics for 
coronary device testing. This tissue-engineering paradigm can be applied to model the 
BBB as well, on a smaller scale. The technique of using scaffolds as a support for ECs 
and astrocytes can be applied for the development of an in vitro BBB. With the use of 
bioreactors, the lab can introduce culture protocols to in vitro models of the BBB that can 
help develop solutions to impact the drug discovery process.   
Previous work performed by Bryan Brandon evaluated the use of one commercial 
system in particular to establish an in vitro model of the BBB [62] (Fig 7). Mr. Brandon’s 
accomplishments led to the development of a protocol for the previous model of the BBB 
in the tissue-engineering laboratory. Mr. Brandon’s first aim was to establish cell culture 
protocols for both bovine aortic endothelial cells and C6 glioma cells, which was 
completed in culture flasks [62]. The second aim was the development of an in-house 
bioreactor that would improve upon the commercial system [62]. The third aim was to 
facilitate the co-culture and analysis of the BBB in vitro model [62]. Later work from Ian 
Mahaffey’s senior project contributed in the initial design of the bioreactor discussed in 
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this thesis. In addition, he created a mandrel to collect electrospun fibers, and evaluated 
scaffolds for use in a BBB model [63].   
	  
Figure 7: CellMax Duo Bioreactor system characterized by Bryan Brandon in the Cal 
Poly Tissue Engineering Lab [62]. 
 
The commercial system utilized in Mr. Brandon’s project, the CellMax Duo 
Hollow Fiber Cell Culture System, was equipped with a hollow fiber bioreactor that 
consisted of sixty polypropylene fibers with 330 𝜇m inner diameters [60,64]. The system 
also included a perfusion pump with positive pressure displacement capabilities that 
could assist the growth of two bioreactors simultaneously [64]. The element of flow was 
developed from the use of various Teflon pump bars that compressed the pump tubing 
and allowed flow from the media reservoir to the bioreactor [64]. Sampling and 
interaction of the extra-capillary space was accessible through transluminal ports on the 
side of the bioreactor. To access the scaffold, destruction of the bioreactor was required 
with the use of a bandsaw to cut through the epoxied ends holding the polypropylene 
fibers. Attempts to retrieve the fibers were possible; however, after immersing the 
scaffolds in fixative, degradation occurred and the loss of data created the need to pursue 
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two bioreactor modules can be run simultaneously [31]. The system utilizes Teflon pump 
bars to depress the pump tubing on the bioreactor module [31]. This forces media to flow 
from the media reservoir, through the gas permeable silicone flow path tubing and into 
the hollow fiber bioreactor module [31].  Flow rates through the tubing are variable and 
are controlled by the electronic control unit (ECU) [31]. Asymmetric pump bars can also 
be used to generate different flow curves [31]. 
 
 
Figure 7: The CellMax DUO pump system with two cartridges and two separate media reservoirs mounted 
on the pumping station [31]. 
 
The CellMax hollow fiber bioreactor consists of 60 polypropylene capillaries 
c ated with ProNectinTM F (See Figure 8). Each fiber has an inner diameter 480ȝm, wall 
thickness 150ȝm, average pore size 0.2ȝm, 100 cm2 inner surface area, and a 1.5mL 
extra-capillary space (ECS) volume. The intracapillary space (ICS) is seeded with 
BAECs while the ECS is seeded with C6 glioma cells. Lumen and ECS are accessible by 
two ports each. The left side tubing is denoted as the inlet port, while the right side port is 
denot d as the outlet port. Sam ling on the inlet and outlet ports is done using a three 
way stopcock (labeled apical ports in Figure 9), while sampling from the ECS can be 
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the second aim in Mr. Brandon’s initial goals: to create a bioreactor that would improve 
upon some of the limiting characteristics of the commercial system.  
A new design for an in-house bioreactor had to decrease the costs of the overall 
system, reuse the system, and allow for users to retrieve the scaffolds after cultivation for 
further assessment. The design of the bioreactor was developed so that alterations to the 
bioreactor could be made in-house. In terms of sterilization, the design had to be 
compatible with techniques available including autoclave and ethylene oxide (EtO). The 
bioreactor also needed to be adaptable to use the PLGA that was currently made in-
house, the ePTFE used in other divisions of the lab, or possibly decellularized vessels.  
1.7 Summary of Overall Thesis Goals 
Based on the need for appropriate in vitro BBB models and the preliminary work 
by Bryan Brandon and the Cal Poly Tissue Engineering lab, the overall goal of this thesis 
was to develop and characterize an in-house bioreactor for the cultivation of a tissue-
engineered blood brain barrier, which met the following requirements. 
The first aim was the design and development of a bioreactor chamber and system 
that could be used to cultivate the BBB. Design criteria were based on the advantages as 
well as the limitations of the CellMax system and the specific needs of the laboratory. 
The goal was to create a bioreactor that was reusable, capable of being sterilized, able to 
be monitored, easily used by students trained in the laboratory, and developed so that 
scaffold extraction is possible.  
The second aim was the characterization of flow and capabilities of the custom 
bioreactor. This involved analyzing flow of the bioreactor using the pumping apparatus 
from the CellMax system, and characterizing the Teflon bars to determine which was 
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optimal for physiological flow conditions. Capabilities of the system that needed to be 
characterized included assembly of the bioreactor, packaging for sterilization, and overall 
use during cultivation. This involved testing the bioreactor under sterile and non-sterile 
conditions, including multi-scaffold and long-term cultivation.  
The third and final aim was to develop protocols for the overall use of the 
bioreactor to ultimately allow co-cultures of BAEC and C6 glioma cells and advance the 
creation of an in vitro model of the BBB. This involved establishing protocols for 
assembly of the bioreactor, insertion of scaffolds, cell preparation prior to integration of 
the bioreactor, cell sodding, and system incubation. Each of these aims will be addressed 
in the subsequent chapters.  
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Chapter 2: Initial Design of BBB Bioreactor, Manufacturing, 
& Costs   
2.1 Introduction 
DIV-BBB has been of interest to researchers for over a decade, with many 
researchers specifically focused on hollow fiber apparatuses [53,57,58,59]. Regardless of 
how the model is constructed, there are certain requirements that a BBB model should 
have. An in vitro model of the BBB must be able to allow expression of tight junctions 
between ECs, which translates to having a restrictive permeability through the 
paracellular and transcellular route [65]. To achieve this, the correct flow conditions, pH, 
and temperature must be maintained to encourage such characteristics.  
The commercial system that was previously used in the tissue-engineering lab, the 
CellMax Duo from Spectrum Labs, provided researchers with models of the BBB that 
expressed low permeability to intraluminal ions, low extravasation of proteins, and low 
expression of glucose transporters [58]. However, analyzing the hollow fibers was 
difficult: destruction of the bioreactor was the only solution to gain access to the fibers, 
and these fibers were only compatible with certain sectioning techniques [57,58].  
Thus there is a need for a new bioreactor design to recapitulate the BBB in a cost-
effective and user-friendly manner. The design requirements were as follows: the 
bioreactor should be made in-house with the resources available at the university, at a 
low cost, reusable, sterilizable using methods available on campus, and allow for scaffold 
extraction.  
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2.2 Initial Designs of the BBB Bioreactor 
Development of a new bioreactor to model the BBB started with initial designs 
that were based on design criteria and limitations of the current model used in the lab. 
Ideas were recorded and drawn into a design notebook before development in a 3D 
modeling program titled SolidWorks (SolidWorks Student Design Kit 2010). Two major 
initial designs were generated, and are described in detail below, including discussion of 
individual parts and overall functionality.   
2.2.1 Design 1 
  The first design originated from Dr. Kristen Cardinal’s Biomaterials class with the 
help of Erik Schulter, Paige Ryan, and Kelly Roberts. Mr. Brandon’s second aim was 
reiterated to the class for this project, with the goal of finding an alternative design to 
alleviate the problems seen in the CellMax system. A new design was developed using 
SolidWorks providing a three dimensional model consisting of a cartridge system with 
two end caps aligned together by two connection bars, an outer housing with two 
transluminal ports, and feeding caps for the inlet and outlet (Fig. 8).  
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Figure 8: SolidWorks drawing of the first design of the bioreactor. Drawing includes all 
of the components and features including the locking system for the cartridge. Designed 
and drawn in SolidWorks by Amin Mirzaaghaeian.  
 	  
The end caps could potentially allow organized scaffold arrangement and 
alignment, which was also facilitated by the connector bars. The assembly of the two 
feeding end caps with the connector bars formed the cartridge that would be inserted to 
the outer housing. The outer housing was to be manufactured out of a transparent 
material to allow visibility of the bioreactor during its culture period. Transluminal ports 
were integrated to permit sampling of the extraluminal fluid, alleviate pressure build up, 
and allow pressure sodding of cells. The outer housing also included a channel that ran 
along the longitudinal axis on the inner diameter of the cylinder, which guided the 
cartridge through the outer housing. Once the cartridge was fitted into the cylinder, it 
would be fastened when twisted counter clock wise into notches, located at the tail ends 
 
Figure 3: Design created for BMED 420 as a new design for an in-house bioreactor to 
mimic the blood brain barrier. The design included an outer housing equip with a inner 
locking system, a cartridge component consisting of end caps and connecting bars, and 
feeding caps on each end of the bioreactor.   
 
When pursuing the in-house route of rapid-prototyping, both Stratasys systems were 
taken into consideration. Unfortunately, after reviewing the material used regularly in the system, 
the P430 ABS plastic used as concluded unsafe for medical use, and only for prototype/display 
purposes. Then research was done to see if a cartridge of medical grade material was possible to 
obtain. However, research concluded that the current Stratasys systems were not compatible with 
such a cartridge, and needed a new system for the material to be used. Next, research went into 
implementing the Objet printer used in the mechanical engineering department. Professor Larry 
Coolidge introduced the system and quoted the designed parts. However, when researching on 
the resin that was being used in the Objet system, it was deemed unsuitable for medical use. At 
this point, in-house rapid prototyping was not an option, which led to the search for rapid 
prototyping companies in the San Luis Obispo area. This research resulted in the possible use of 
Alltec Inc., a rapid prototyping company that was also associated with our University’s 
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of the outer housing, perpendicular to the longitudinal channels (Fig. 8). Feeding end 
caps were then installed onto the ends of the outer housing for induction of media at the 
inlet. After approval from Dr. Cardinal, a project was created to further develop the 
design and manufacture the new bioreactor.	  
2.2.2 Evaluation of Design 1 
The design was brought to David Laiho to assess design and manufacturing 
options. His assessment concluded that the inner locking mechanism was impossible to 
manufacture if the housing was to be made in one piece. In terms of securing the 
scaffolds, the scaffold cap provides holes where the scaffolds can be glued. However, for 
the scaffold caps to be reusable, securing the scaffolds with glue would make it difficult 
for multiple uses. To proceed with this scaffold cap design would require finding a 
medical grade adhesive that had a complementary solution to degrade the glue for 
installation of new scaffolds. When installing transluminal ports, machining a hole on a 
cylindrical surface raised possible leaking issues. To proceed with this idea, he suggested 
machining the hole and glue around the component that would represent the port, or 
install an O-ring around the component to prevent leaking. Furthermore, Mr. Laiho 
suggested keeping the cartridge, but to develop an alternative way to secure the cartridge 
inside the outer housing. After reviewing the issues of securing the cartridge and 
scaffolds, sealing the bioreactor, and including transluminal ports, Mr. Laiho’s 
assessment led to the decision to design a new bioreactor. The overall evaluation of the 
first design is summarized in Table I below. 
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Table I: Design evaluation for initial design 1 
 Result Comments 
Manufacturing  Complicated Locking system impossible 
Cost Variable Material dependent  
Ease of Use Yes Cartridge reduces total parts 
Reusable Yes Sterilization procedure 
dependent  
Sealing No Friction not enough to seal 
Multiple Scaffolds Yes Organized arrangement 
 
2.2.3 Design 2 
  Based on the evaluation of the first design, the second design of the bioreactor 
included several of the same components, but differed in the design of each component. 
The initial cartridge idea was kept with a design that would allow the cartridge to be 
pushed through an outer housing (Fig. 9).  
	  
Figure 9: Solid drawing of cartridge designed to be pushed through the outer housing. 
Drawn by Amin Mirzaaghaeian.  
 
  
 
Figure 4: Solid drawing of final design including the outer housing, two outer caps, two 
scaffold caps, and scaffold bar. 
 
 
 
OUTER CAP 
The first component, the outer cap (See Figure 5), was designed to have an O-ring groove 
on the outer diameter to create a seal between the C6 glioma media and the outside environment. 
Figure 6 shows the cross section displaying the inner design of the outer cap. Some of the 
specific details of the design include a small portion of space to connect tubing to the outer cap 
allowing the flow of BAEC media to the scaffold fibers, a conical shape feature allowing 
uniform distribution to all fibers and avoiding fluid turbulence, and an inner threading allowing 
the attachment of the scaffold cap to the outer cap.  
 
Figure 5: Machined outer caps including O-ring groove, outlet hole, conical region, and 
inner threads.  
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The cartridge was composed of two scaffold caps stabilized with a rod that would 
fit in the middle of each cap creating a dumbbell configuration. Each scaffold cap would 
have eight installation ports for scaffolds to be glued into. Once the scaffolds and 
stabilization bar were fitted to each scaffold cap, the scaffold caps would be fitted into 
two outer caps that would complete the cartridge configuration. The two outer caps 
would allow flow through the inlet and outlet to the media reservoir. Sealing of the 
bioreactor would be achieved by introducing an O-ring groove on the outer diameter of 
the outer caps. Once the cartridge was fitted with O-rings it would then be pushed 
through the inner diameter of the outer housing until both sides of the cartridge was 
secured inside. Transluminal ports were developed with holes machined on the outer 
diameter of the outer housing, and fittings to be screwed in with an O-ring fastened 
around it to prevent leaking.  
2.2.4 Evaluation of Design 2 
 Design 2 overcame the limitations seen in Design 1 with the implementation of an 
improved cartridge apparatus that would allow easier scaffold installation and sealing of 
the bioreactor. With a larger outer housing diameter, the O-rings fastened around the 
fittings were thought to be adequate to prevent leaks. Although the new cartridge design 
was sufficient to seal the contents of the bioreactor, having to extract the scaffolds at 
different time points was not a function included in this design. The method of pulling the 
cartridge out, replacing the media, and avoiding contamination would be very 
complicated. Further development was needed to complete the design of the bioreactor. 
The table below describes the evaluation of Design 2.  
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Table II: Design Evaluation for initial design 2 
 Result Comments 
Manufacturing  Possible  CNC or Lathe  
Cost Still Variable Material dependent  
Ease of Use Yes Cartridge reduces total parts 
Reusable Yes Sterilization procedure 
dependent  
Sealing Yes O-ring grooves used for 
sealing 
Multiple Scaffolds Yes Organized arrangement 	  
2.3 Design 3  
 This was developed using the ideas of the second design, but altering the outer 
housing to be equipped with a detachable window for scaffold extraction. In addition, 
plans to glue scaffolds into the scaffold caps was rejected, and suturing the scaffold onto 
barbs was chosen. To seal the window and to prevent leaking, silicon rubber would be 
implemented around the edges of the window. The design of the bioreactor included two 
scaffold caps, a stabilization bar, two outer caps, bioreactor cap, and an outer housing. At 
this stage of development, each part was modeled and dimensioned in SolidWorks (Fig. 
10). Complete solid drawings can be referred in Appendix B. The next step was to find 
the most efficient method for manufacturing that would fulfill the requirement of building 
the bioreactor in-house.  
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Figure 10: Solid Drawing created prior to manufacturing with all features dimensioned 
and specified. 
2.4 Manufacturing  
 Campus resources used to manufacture the bioreactor included rapid-prototyping 
and machining methods. Rapid prototyping was first explored with the plan of utilizing 
the Stratasys systems used in the Biomedical Engineering Department. The advantage of 
using this system was the short time it would take to manufacture each of the parts; the 
components were estimated to take a couple of days to complete. This method of 
manufacturing was rejected after discovery of the material used and the system 
compatibility issues of the Stratasys system. The material used, P430 ABS plastic, was 
mentioned only for creation of prototypes and not considered biocompatible. A focus was 
then directed toward other Stratasys products to determine if they supplied materials used 
for medical devices. ABS-M30i and PC-ISO (polycarbonate-ISO) were two materials 
found suitable for biocompatibility that could also be EtO sterilized. Unfortunately, the 
cartridge that supplies these materials was not compatible with our models on campus. To 
use these materials, the department would have needed to purchase the FORTUS system, 
which was not feasible. Another option for rapid prototyping included equipment in the 
Mechanical Engineering Department, such as the Objet printer. With the help of Larry 
Coolidge, the Objet printer system was investigated for use to manufacture the bioreactor. 
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The Objet system was known for its higher resolution compared to other fused deposition 
modeling systems provided on campus. Cost for using the printer was $25 for the job and 
an extra fee depending on how much resin was used. The resin used in the Object system 
(Eden250) was first assessed for its biocompatibility. The materials fact sheet for the 
resin indicated that it was not suitable for medical device use. Therefore, of the possible 
options for manufacturing, rapid prototyping on campus was rejected. The last option for 
rapid prototyping was a company here in San Luis Obispo. Alltec Inc. was found based 
on its connection with the Mechanical Engineering Department. Manufacturability of this 
design was discussed with Randal Dennis, a mechanical engineer from Alltec Inc. After 
the assessment that the material would need to be sterilized and medical-grade, Dennis 
concluded that Alltec could not fulfill those requirements and recommended machining 
the parts instead.   
 Machining was considered the final option in creating the bioreactor. A question 
of where to machine the parts was raised based on the limiting factors of time and money. 
The options were between outsourcing to a machinist and having it done by a student. 
Material research was required before a decision was made. This research led to selecting 
316-stainless-steel based on its mechanical and material attributes. The disadvantage of 
this material was that it required a slow machining procedure with a coolant of either gas 
or water to assess heating of drill bits. As a result, a professional machinist was chosen to 
help assess the complex machining and to manufacture the parts. Design of the bioreactor 
components were finalized in SolidWorks (Appendix B) and sent for manufacturing. Two 
outer caps, two scaffold caps, and a stabilization bar were machined out of 316-stainless-
steel.  
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 The one part of the bioreactor that was manufactured in-house was the outer 
housing of the bioreactor. Acrylic was chosen for its transparency, ease of machining, 
and low cost. The acrylic outer housing was dimensioned to be 6” in length and 3” in 
diameter representing the overall size of the bioreactor. The Mechanical Enginnering 
Department’s Bonderson 60 machine shop was used for creating the outer housing. 
Milling was used to create the window, while a bandsaw was used to create the bioreactor 
top, and drill press to create all the outlets (Fig. 11).  
 
 
Figure 11: Outer housing machined in-house with bioreactor cap and silicon gasket 
material to create sealing of window 	  
Around the edges of the machined window, silicon rubber with a durometer rating 
of 50A and adhesive backing supplied by Mcmaster-Carr was installed (5787T63). 
Perpendicular to the longitudinal axis of the outer housing in the center of the housing, 
two #10-32 holes were drilled and tapped to allow fittings to be threaded onto, 
representing the transluminal ports of the bioreactor.  
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The bioreactor cap consisted of a 3 x 3” piece of acrylic manufactured from a 3.5 
x 3.125” cast acrylic tube. The concave side of the cap was fitted with the same silicon 
rubber applied on the outer housing. The cap would be secured onto the outer housing 
with worn-driven hose clamps with thumbscrews. The clamps would be positioned at the 
ends and in the middle of the bioreactor cap.   
2.5 Machined Parts and Bioreactor Components  
2.5.1 Outer Caps  
 The outer caps represent the two ends of the bioreactor, with no directional 
orientation when choosing which to be the inlet or outlet. The diameters of the caps were 
slightly less than 2.5”. Internally, each cap contains an inlet or outlet shown in Region I 
in the diagram below (Fig. 12). The inlet lumen then leads to Region II, the conical 
region.  
	  
Figure 12: Schematic displaying different internal regions of the outer cap. 
 
The design of this feature was intended to avoid turbulent flow and to provide 
uniform distribution of fluid to a surface. Region III represents where the scaffold cap 
would be threaded and secured into the outer caps. On the outer diameter of the outer 
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caps, an O-ring groove was designed to allow ASM-228 silicon O-rings to sit in the 
groove and provide the required seal of the bioreactor (Fig. 13). Unfortunately, there was 
an error dealing with an incorrect reference dimension during the manufacturing process. 
The result of the error was a groove depth twice the amount that was originally specified 
based. This error was taken in account and discussed further in phase I of initial testing.  
 
	  
Figure 13: Machined outer caps with O-ring grooves to allow fitting of O-rings to create 
seal when inserted into the outer housing. 
2.5.2 Scaffold Caps & Stabilization Bar 
 This component of the bioreactor consisted of a scaffold cap with and without a 
stabilization bar (Fig. 14). These caps were designed to attach eight tissue scaffolds, 1mm 
in diameter, using 2mm holes machined into the caps. One of the scaffold caps was 
designed to allow insertion of the bar into a 0.25” diameter hole creating the smaller 
“dumbbell” configuration previously mentioned (Fig. 14). This was implemented so that 
scaffolds could be installed on the one scaffold cap connected to the stabilization bar, and 
would align to fit into the other scaffold cap. The scaffold caps would then be threaded 
into the other caps to create the cartridge configuration that would later be inserted into 
the acrylic outer housing.  
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Figure 14: Machined scaffold caps with and without stabilization bar. Initial “dumbbell” 
configuration is achieved when insertion of stabilization bar into other scaffold cap. 
2.5.3 Scaffolds & Barbs 
 In the Tissue Engineering Lab, there are two types of scaffold material used: 
ePTFE and PLGA. PLGA is electrospun in-house and serves as another division in the 
BBB research. Fibers spun are on the order of microns in the range of 2-3 𝜇m [66]. The 
size of the scaffolds can be adjusted with the use of different sized mandrels. For the 
BBB, the goal was to have scaffolds in the 1mm range, however, based on the small scale 
of the fitting required for such sized scaffold, custom machining of a barb would have 
included additional time, money, and research and development. The actions to develop 
these barbs were not included in this thesis. However, 2mm barbs were commercially 
available from Qosina, a fitting/accessory company centered in wholesale, and therefore 
this size was selected for the BBB scaffolds. A product sample of female luer lock to 
barb connector was donated to the project by Qosina, allowing the use of 2mm scaffolds 
(Fig 15). Scaffolds were spun on a miniature 304 stainless steel 15-gauge tube (Fig. 16).  
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Figure 15: Qosina barb designed to fit 2mm scaffolds. 
 
	  
Figure 16: PLGA scaffold spun on precision miniature 304 stainless steel 15-gauge tube 
[66]. 
2.5.4 Fittings and tubing 
 Fittings for the bioreactor included one- and three-way stopcocks, Y-Connector-
1/8” barbs, luer barbs, and tube clamps. Tubing included both 0.25” silicon and 0.125” 
gas permeable tubing that led the path of flow from the inlet to outlet. Female luer 
threaded barbed fittings and male luer lock barbed fittings were used to connect tubes and 
other fittings to each other. Barb to ¼” thread fittings used to connect the 0.25” tubing 
were threaded at Region I of each outer cap. End caps were used to stop flow out certain 
exits or during 1, 2, or 3 scaffold set-ups to block flow in any open scaffold ports. Male 
luer-to-thread and male-to-male collar fittings were used to connect the Qosina barbs. 
Tube clamps were used externally where flow needed to be stopped (Fig. 17). 
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Figure 17: Diagram of all fittings used in bioreactor system except for Qosina barbs. 1.) 
Barb to 4-25 thread. 2.) Male luer integral lock ring to 10-32 special tapered thread. 3.) 
Female-female connector. 4.) Female luer thread barbed fittings.  5.) End caps. 6.) Male-
to-male luer lock connectors. 7.) Female luer thread style with ¼” hex to 10-32 UNF 
thread. 8.) Male luer thread barbed fittings 9.) Y-Connector-1/8” barbs. 10.) 3-way 
stopcock. 11.) 1-way stopcock. 12.) Tube clamps. 13.) 0.25” silicone tubing. 14.) 0.125” 
silicone gas permeable tubing. Part information is available in Appendix B. 
2.5.5 Media Reservoir & Perfusion Pump  
 The media reservoir consisted of a 50ml conical, which could house media 
corresponding to a specific cell type. The conical cap was integrated with two holes 
corresponding to an inlet and outlet of the reservoir. The outlet port of the reservoir 
extends down to the bottom of the conical, while the inlet port was located at the 
reservoir cap. The extension of the outlet port was to allow the media level to decrease to 
the lowest amount before installing a new media reservoir. Outlet fluid from the 
bioreactor entered at the cap, while the oulet fluid exited at the base of the conical (Fig. 
18).  
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Figure 18: Media reservoir 50ml conical with inlet and outlet shown. 
 
 The perfusion pump that was used was the same pump used in the CellMax 
system. The pump was supplied with its own pump tubing and tubing holder that was 
mounted to the pumping mechanism used to produce flow. The pump was also equipped 
with a switch that allowed eleven modes of pump speeds (Fig. 19). For the CellMax 
system, each speed had been characterized and associated values of milliliters per minute 
were given [62,64].  
	  
Figure 19: Pump system used during experiments that required flow. 
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2.6 Cost 
 The system needed to be cost effective, especially when compared to the CellMax 
system, and therefore the overall cost was assessed. The cost of the bioreactor system was 
broken down into stainless steel components, acrylic, O-rings, tubing, and fittings. The 
following table presents the overall cost breakdown. Information regarding vendor, 
product numbers, quantity, and pricing can be found in Appendix B. This improved upon 
the $500 cost for one CellMax hollow fiber bioreactor for a single use. The $200 cost for 
the stainless steel parts was an up-front cost, with no maintenance fees or recurring 
charges.  
 
Table III: Bill of materials with costs included showing total cost of bioreactor system. 
Stainless Steel $200 
Acrylic Outer Housing  $34.42 
Acrylic Bioreactor Cap $35.17 
Custom O-rings $25.82 
Silicon sheet material  $34.45 
Custom Internal O-rings $17.41 
Female Luer Lock to Barb Connector Donated 
Male Luer Integral Lock Ring to 10-32 
Special Tapered Thread  
$31.82 
Female Luer Thread Style with ¼” Hex to 
10-32 UNF Thread 
$16.50 
Total  $396.59 
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Chapter 3: Initial Testing of Bioreactor 
3.1 Initial Testing 
Once all associated parts including fittings and O-rings were purchased, and the 
bioreactor was constructed, initial testing of the bioreactor was performed (Fig. 20). The 
bioreactor was tested for leakage, the ability to be sterilized, and its ease of use. The tests 
performed were separated into three phases I, II, and III. Phase I testing dealt with any 
test protocols that involved fluids (water or media) including leak tests, flow 
characterization, and overall behavior of the bioreactor when internally exposed to fluids.  
	  
Figure 20: Initial bioreactor with scaffold cap, outer cap, outer housing, bioreactor cap, 
and clamps. 	  
Phase II dealt with scaffold installation, packaging, and sterilization of the 
bioreactor. Phase III dealt with testing utilization in a laminar flow hood and application 
of cell culture methods with the bioreactor. Several iterations of design changes to the 
bioreactor were established through these phases of initial testing, all leading up to the 
final design of the bioreactor described in the next chapter.  
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3.2 Phase I 
3.2.1 Leak Tests 
  The tests under Phase I were used to evaluate the design of the bioreactor and its 
function when the bioreactor was internally exposed to fluid. Leak tests were the first of 
many water experiments used to assess the bioreactor’s function. Water was chosen as it 
had viscosity similar to the media used in the lab, but was cheap and easy to use. The seal 
of the outer caps was analyzed first. As the groove for the outer caps was larger in depth 
then specified, use of the O-rings that had been purchased for the called out groove were 
first utilized. This resulted in stacking the O-ring to see if a seal could be achieved. 
During testing, outer caps were first fitted with O-rings using 3 or 4 in some cases. The 
O-ring stacking was possible with the use of O-ring picks (Fig. 21). The outer caps would 
then be pushed onto the ends of the acrylic outer housing and water would be filled in the 
extraluminal space. The bioreactor cap would then be installed and resulted in a 
bioreactor filled with water.  
	  
Figure 21: O-ring picks used to orientate or remove O-rings in O-ring groove. 	  
Once filled, the bioreactor was held vertically, horizontally, and even shaken to evaluate 
any leaking that might occur. The bioreactor was then placed on a test tube rack, which 
was then placed on a paper towel. Leaks were measured if water dropped onto the paper 
towel marked with sharpie along the bioreactor’s perimeter (Fig. 22).  
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Figure 22: Bioreactor under leak test with marked perimeter to detect leaks. 
 
With a drop of water, the ink would spread and once dried, display a distortion to the 
perimeter originally marked. The stacking of O-rings to create a seal worked, however 
one disadvantage was the difficulty of pushing the end caps into the acrylic outer 
housing. The difficulty originated from the high durometer specified for the O-rings. The 
next step was to apply O-rings with softer durometers to decrease the complexity of 
overall use. O-ring selection was based on material and compatibility with sterilization 
procedures used on campus, including EtO and autoclave. The table below shows all the 
O-rings that were tested to see which was the most optimal for use (Table IV).  
 
Table IV: List of O-rings tested 
O-Ring Comment 
Hard Silicone O-ring, As568 Dash Number 228 Autoclave and EtO capable 
Hard Buna-n O-ring, As568a Dash Number 228 Not recommended for Autoclave or 
EtO 
Pfte O-ring, As568 Dash Number 228 Stiffer than Silicone and Buna-n O-
rings. Produces too much friction. 
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As softer durometers were used in the outer caps, there was difficulty with the O-rings 
remaining in place and their ability to seal. The use of softer durometers increased ease of 
use of the bioreactor but decreased the ability to create a seal. The next idea was to 
change the design of the acrylic outer housing to keep the low durometer O-rings and 
maintain ease of use. This transitioned from the first to second generation acrylic outer 
housing.  
 The second-generation outer housing was designed with the same dimensions, but 
given a longitudinal cut .125” in width (Fig. 23).  
	  
Figure 23: Second-generation housing designed with 0.125” longitudinal cut and silicon 
material filling the gap. 
 
The window located on the acrylic outer housing was larger to provide more space to 
reach into the bioreactor. This gap was then replaced with a piece of silicon rubber with 
an adhesive backing with a durometer of 50A. Stainless-steel hose clamps used to secure 
the bioreactor cap were used to clamp the acrylic outer housing tightly around the outer 
caps at the O-ring grooves. When tested, assembly was still difficult, as it required two 
people to pull open the outer housing and slide in the cartridge. When testing with water, 
leaking had occurred over several iterations of the test. As the bioreactor cartridge would 
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slide into the housing, O-rings originally fixed in their grooves moved out of place 
affecting the seal (Fig. 24). This was assessed by repeated cartridge insertion.  
 
	  
Figure 24: Second-generation bioreactor housing with cartridge (bottom) and housing 
(top) separated. Red arrows indicate the interfaces where leaks occurred. 	  
In some cases, over tightening of the clamps would over compress the 
longitudinal gap deforming the outer housing to an ellipse where leaking would be 
apparent. At this stage of testing, a more reliable housing and seal were needed. Design 
changes went back to the first generation housing, but a focus was made to find better 
sealing techniques. 
 One solution was the manufacturing of a custom O-ring in-house to seal the 
bioreactor along with using the first generation acrylic outer housing. A silicon sheet of 
7/16” in thickness was placed in the laser cutter provided by the Bonderson 60 machine 
shop. Based on the dimensions of the O-ring groove, a square O-ring was created (Fig. 
25).  
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Figure 25: Custom square O-ring machined in-house using laser cutter. 
 
Testing the seal on this design resulted in a very small leak. This was a result of a tilt that 
was noticed, as the component was situated in the outer housing. This resulted in leaks 
that would affect long-term cultivation studies.  
  Another solution was to utilize the area before and after the O-ring groove to 
place a silicon material around the outer diameter of the outer caps. The material was a 
silicon sheet with foam integrated within the core of the material, and an adhesive 
backing. Lengths were cut and dimensioned based on the perimeter of the outer diameter 
of the outer caps. Assembly into the outer housing was accomplished with no 
complications compared to previous uses of O-rings (Fig. 26).  
	  
Figure 26: Assembled bioreactor with silicon foam sheet material used to seal the 
bioreactor. 
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No signs of leaking were apparent when tested with water. This design became a 
potential solution to sealing the bioreactor, but complications started to arise when using 
this design for subsequent tests. It was discovered that the material was not able to create 
the robust seal during repeated tests. Every test meant replacing the material on the outer 
cap, which involved using acetone on the outer caps and 70% isopropyl alcohol on the 
bioreactor cap to remove the residual adhesive left from the material. In terms of cost, 
this design would not have been efficient. In terms of upkeep of the bioreactor, this 
design increased maintenance time. By choosing a durometer one tier higher, a silicon 
material without the foam core was chosen.  
 The final solution was a combination of the silicon sheet material and the custom 
O-ring (Fig. 27). This combination increased the surface area of the seal and alleviated 
the tilt observed when just using the custom O-ring. The silicon sheet material was 
designed to be permanent on the outer diameter of the outer cap. A water test was 
conducted to assure that no leaks would occur under this design. The results of the water 
tests confirmed that this was the final iteration in the design to seal the bioreactor.  
	  
Figure 27: Final solution to sealing the bioreactor, using combination of custom square 
O-ring and use of silicon material along the outer diameter of the outer cap. 	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To seal the contents within the outer caps from the bioreactor chamber, custom 
internal O-rings were placed between the scaffold cap to outer cap interface at the end of 
the threading (Fig. 28). To test the efficacy of the custom O-ring, water was pumped to 
one side of the bioreactor and the leak potential of the outer cap-scaffold cap interface 
was assessed. The implementation of this feature inhibited content intended for the 
scaffolds from escaping into the bioreactor chamber.  
	  
Figure 28: Custom internal O-ring used to seal inner contents of the bioreactor. 
3.2.2 Flow Characterization 
 
 When using the bioreactor system with the perfusion pump used for the CellMax 
system, characterization of flow was required to know what kinds of shear stresses that 
would be exposing the cells to. Physiological shear stresses in the capillaries of the BBB 
range from 1-2 dynes/cm2 [53,57,60]. The bioreactor was assembled with 2mm ID PLGA 
scaffolds sutured onto barbs. The tubing and chamber were filled with water and primed 
until all air in the system was removed. Three sets of flow rates were obtained, one for 
each Teflon bar including blunt end, cut end, and low flow rate pin (Fig. 29,30). Flow 
rates in milliliters per minute were measured at each of the eleven settings provided by 
the CellMax pump (Table V). Pipettes were used to measure the fluid that would exit the 
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system in one minute. Using the theoretical definition of laminar flow shear stress, flow 
rate of milliliter per minute was converted to dynes/cm2 (Eq. 1) (Fig. 31). Values obtained 
show similar values compared to flow rate and shear stress characterization of the 
CellMax system conducted by Bryan Brandon (Table VI). 
	  
Figure 29: Three Teflon bars that were included in the CellMax pump system. The bar on 
the left, the blunt end pin, is capable in creating the highest flow rates. Bar in the middle, 
cut end pin can achieve lower flow rates. Lastly, the low flow rate pin achieves the lowest 
flow rates. 
	  
Figure 30: Flow rates in ml/min referring to the rate experienced in bioreactor system 
with four scaffolds. 
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Figure 12:  The three different types of pump bars available to achieve different flow rate profiles. The bar 
on the right is called the “blunt end pin” and can achieve the highest flow rates due to the large surface area 
on the bottom face. The middle bar is called the “cut end pin” and achieves lower flow rates than the blunt 
end pin due to its smaller surface area on the bottom face. The pump bar on the right is called the “low flow 
rate pin” and is used to achieve the lowest flow rates due to its small surface area. 
 
After the tubing had been connected to the pumping system, flow rates were 
determined for each of the three separate Teflon pump bars by measuring the volumetric 
flow rate through the bioreactor and tubing. Next, shear stress calculations were 
performed to determine the amount of shear stress endothelial cells will be exposed to 
inside the lumen of the hollow fibers. Laminar flow shear stress over the apical surface of 
endothelial cells cultured in a hollow tube of artificial capillary fibers is theoretically 
defined as: 
 
Ĳ = (4ȘQ)/(ʌr3) 
 
where:  Ș = viscosity ((dyne sec)/cm2) 
 Q = fluid flow rate (cm3/sec) 
 r = internal radius of hollow fiber (cm) 
 
This allowed for the determination of proper flow rates in order to ensure the most 
physiologic environment for BAECs to grow in, while also ensuring the maximum 
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Equation 1:       τ = (4ηQ)/(πr3) 
 
where:  η = viscosity ((dyne sec)/cm2) 
 Q = fluid flow rate (cm3/sec) 
                         r = internal radius of hollow fiber (cm) 	  	  	  
	  
Figure 31: Each rate in dynes/cm2 refers to the rate experienced in each scaffold in the 
Final BBB bioreactor. 
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Table V: Table displaying flow rates in ml/min and shear stress in dynes/cm2 of the final 
bioreactor. These rates were obtained when the system was fitted with four scaffolds. 
Each rate in ml/min refers to the whole system with four scaffolds. Each rate in 
dynes/cm2 refers to the rate experienced in each scaffold. 
 Blunt End Pin Cut End Pin Low Flow Rate Pin 
Settings ml/min dynes/cm2 ml/min dynes/cm2 ml/min dynes/cm2 
1 7.2 2.60 3.9 1.4 0.89 0.32 
2 13.6 4.90 7.8 2.81 1.5 0.54 
3 20.1 7.24 11.5 4.14 2.5 0.90 
4 27.5 9.90 16.7 6.01 3.3 1.19 
5 36.3 13.10 22.7 8.17 4.2 1.51 
6 44.1 15.88 27.3 9.83 5.4 1.94 
7 51.4 18.51 31.8 11.45 6.3 2.27 
8 58.8 21.18 35.2 12.68 6.8 2.45 
9 66.5 23.95 42.8 15.41 7 2.52 
10 76 27.37 49.8 17.93 8 2.88 
11 85 30.61 53.4 19.23 8.79 3.17 
 
 
Table VI: Flow rate characterization performed by Bryan Brandon. Each rate in ml/min 
and dynes/cm2 refers to the CellMax system [60] 
 Blunt End Pin Cut End Pin Low Flow Rate Pin 
Settings ml/min dynes/cm2 ml/min dynes/cm2 ml/min dynes/cm2 
1 9 6.8 4.5 3.4 0.8 0.61 
2 16 12.1 8.5 6.4 2 1.52 
3 23 17.4 13 9.8 2.75 2.08 
4 30 22.7 17.5 13.3 3.75 2.84 
5 35 26.5 21 15.9 4.25 3.22 
6 42 31.8 26 19.7 5 3.79 
7 50 37.9 31 23.5 5.5 4.17 
8 57 43.2 36 27.3 6.25 4.73 
9 67 50.8 39 29.5 7 5.3 
10 71 53.8 43 32.6 7.5 5.68 
11 80 60.6 48 36.4 7.25 5.49 	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3.3 Phase II  
 Scaffold installation was characterized by ease of installation, time spent in the 
hood, and the risk of contamination. Installing the scaffolds before or after sterilization in 
a laminar flow hood was evaluated. Installation while in the hood was the more difficult 
of the two. This method required the use of sterile gloves so that the user had the ability 
to pass his or her hands over objects. Sterile sutures were needed to secure the scaffold 
onto the barbs. This procedure was also the most time consuming, taking close to 20 
minutes per scaffold. In addition, this led to increases in window dimensions to account 
for more space for users to enter the bioreactor chamber. This method was challenged by 
installation of scaffolds prior to sterilization. This procedure of installation reduced the 
risk of contamination and decreased time spent during experimental set up. The 
installation of scaffolds prior to sterilization was determined to be the more efficient 
method based on time of installation and difficulty for the user.  
3.3.1 Packaging & Sterilization 
Packaging of the bioreactor was another phase of testing to see if the bioreactor 
could comply with techniques already used in the lab. Packaging of the Tupperware 
bioreactor involved the use of Paper/Film Gas/Steam Sterilization Pouches supplied by 
Cardinal Health. The dimensions for the large blue film self-seal pouches were 7.5 x 13”, 
fitting the Tupperware bioreactors quite well. However, the bioreactor system was too 
large to fit into one pouch, so the system was divided into three bags (Fig. 32). 
	   49	  
	  
Figure 32: Bioreactor packed in three 7.5” x 13” sterilization pouches. 
 
To increase efficiency and to decrease time spent in the hood, larger pouches were 
purchased so that the whole system could be fully assembled, sterilized, and opened in 
one pack. The larger packs had dimensions of 13 x 18”, and were able to fit the 
bioreactor and pump tubing (Fig. 33).  
	  
Figure 33: Bioreactor system packaged in one 13” x 18” sterilization pouch. 
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Sterilization was the other half of phase II testing, exploring methods available on 
campus and in the Tissue Engineering Lab. The Veterinary Clinic on campus provided an 
Ethylene Oxide sterilizer, while an autoclave was available in the Biomedical 
Engineering Department. Both methods were investigated to assess which was best, 
starting with the autoclave since it was easily accessible.  
The specifications of the autoclave included a temperature range of 250-300oF. 
All main components of the bioreactor including outer housing, outer caps, scaffold 
caps/bar, internal outer cap O-ring, and internal fitting had melting temperatures above 
the temperature specifications of the autoclave. Before placing the bioreactor inside the 
autoclave, samples from each of the main components of the bioreactor were placed in 
the sterilizer and processed under the autoclave setting “Packs”. Measurements of 
dimensions were taken for each sample before and after sterilization to assess 
deformation. Once each sample was cleared to withstand autoclave sterilization, testing 
the bioreactor fully assembled was next to be done. Once packaged, the bioreactor was 
set to undergo the “Packs” setting for the duration of one hour (Fig. 34).  
	  
Figure 34: Bioreactor packages placed into autoclave for sterilization. 
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When sterilization finished, the package needed time to cool off, as the stainless-
steel parts were still hot. Damage was first seen when the acrylic outer housing had 
warped and deformed near the interface of the outer caps. This was first seen to be a 
problem, but additional leak tests proved that the sterilization processes did not ruin the 
seal of the bioreactor. The second observation was that the stopcock fittings were loose 
and could no longer engage in their locking positions. This became problematic as the 
autoclave shrunk internal parts of the stopcock. This showed that with the bioreactor fully 
assembled, autoclave was not a feasible method for sterilizing.  
 EtO sterilization was then assessed, posing as an alternative to autoclave 
sterilization. The tissue-engineering lab used the EtO sterilizer at the Vet Clinic to 
sterilize bioreactors intended for sterile set-ups. The lab was charged per lot for the 
ethylene gas used, and services were only available on the weekends. The specifications 
for EtO include a temperature range of 100-140oF and very minimal pressures. The 
sterilization differs from autoclave, as it does not use steam to kill microorganisms, but 
instead uses gas to sterilize. The one disadvantage of using EtO was the residue that 
could have resided on the surfaces or pores of materials. This was a potential challenge 
for pre-loading PLGA scaffolds into the bioreactor prior to sterilization as there was 
concern that the residue could be trapped within the pores of the scaffold, and would 
cause a cytotoxic effect on the cells. Sterilizing with EtO meant that the bioreactor 
system was fully assembled and left as a semi-closed system. Semi-closed refers to 
having one of the transmural ports open to allow gas to enter the bioreactor chamber and 
sterilize scaffolds. The bioreactor cap port was also open to allow gas entry into the 
chamber as well as a way for exiting gas and pressure. At the end of the sterilization 
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cycle, the process did not damage the bioreactor. EtO therefore became the main 
sterilization process for the bioreactor, but later investigation of cell viability was 
required to assess whether the scaffolds could be preloaded, and if the residue was killing 
the cells [67].   
3.4 Phase III 
 Phase III of initial testing consisted of testing the bioreactor in the hood and 
applying cell culture methods. Before testing inside the hood, a grid was created to mimic 
the hood dimensions on a bench top, in order to determine how the packaged bioreactor 
would enter, be placed, and opened in the hood. Orienting the packaged bioreactor to the 
upper right area of the hood left the middle area for loading of bioreactor media, as well 
as placing end caps to open ports. Assessing how to insert bioreactor media into the 
chamber involved strategies to reduce risk of contamination (Fig. 35).  
	  
Figure 35: Funnel technique used to insert bioreactor media into bioreactor chamber. 
 
The first technique was to open the hose clamps and remove the bioreactor cap to allow 
entry into the chamber. It was then discovered during filling of the bioreactor chamber, 
that as window size increased, space to hold the fluid in the chamber decreased. This 
risked the users ability to fully submerge the scaffolds with bioreactor media. During 
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single or double scaffold set-ups, this would not be a problem, as the two scaffolds would 
be situated on the lower level. With the time of installing the scaffolds and the addition of 
bioreactor media into the chamber, this method took an hour in the hood. To address time 
constraints and risk of contamination when opening the bioreactor, a funnel technique 
was used.  This funnel technique included a glass funnel and the transmural outlet tubing. 
Pouring of the bioreactor media into the chamber was accomplished without ever opening 
it. This allowed the media level to go past the outer diameter of the outer caps, and fully 
submerge four scaffolds (Fig. 36).  
	  
Figure 36: Process to fully submerge scaffold barbs. 
 
Compared to the non-funnel method, the funnel approach took 15 minutes and 
decreased the amount of difficulty using the bioreactor. Because of this, the funnel 
method was chosen to be in the final protocol for use. This also lead to the design change 
of the bioreactor cap to be fitted with a transmural port, to relieve pressure as the 
bioreactor chamber was being filled. Based on students using the bioreactor to gain 
feedback in accessibility, it was determined that the stabilization bar hindered navigation 
inside the chamber during scaffold installation. After assessment that more room could be 
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obtained in the absence of the bar, the stabilization bar was removed and replaced with a 
plug. The outcome of all the initial phase testing resulted in the final design of the 
bioreactor with protocols for overall use and maintenance, as described in the following 
sections. 
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Chapter 4: Final Design of BBB Bioreactor  
4.1 Final Design 
 This chapter describes the final components and assembly of the bioreactor 
system. The custom, in-house bioreactor system was required to meet the following 
design constraints: sterilizability, reusability, easy of use, leak-free, and culture up to four 
scaffolds at once. The results of the initial phase testing described in the previous section, 
as well as the associated design changes led to the final design of the bioreactor described 
in this chapter (Fig. 37). Finalized protocols were also created including protocols for 
assembly, conditioning, cell culture, take down, and cleanup (Appendix D).   
	  
Figure 37: Final design of bioreactor system with pump and media reservoir. 
4.2 Components  
This final version of the bioreactor improves upon the components seen in 
previous designs. In this version, the stabilization bar was removed to provide more space 
for scaffold installation. These scaffold caps were fitted with #10-32 holes for both male 
and female luer-to-thread fittings. To prevent leaks the custom square O-ring and the 
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silicone strip material was mounted on the outer diameter of the outer caps. Two 
transmural ports were located on the side of the bioreactor to enable sampling, filling, and 
allow for transmural flow as shown in Figure 38. Stainless-steel hose clamps were used 
to secure the bioreactor cap providing a seal. The transluminal port located on the cap is 
only accessed during introduction of bioreactor media to relieve pressure build up. 
Finally, a 50ml conical was included in the tubing to serve as a media reservoir.  
 
 
 
4.3 Assembly 
 Constructing the bioreactor was a four-part process including scaffold installation, 
outer cap insertion, bioreactor cap placement, and connecting the appropriate tubing. A 
detailed step-by-step protocol can be found in Appendix D, and is summarized below. 
Assembly, which took approximately twenty minutes, was designed so that the whole 
system was a semi-closed system before EtO sterilization.  
Figure 38:Transmural outlets located on the side 
of the bioreactor.  
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4.3.1 Scaffold Cap Preparation  
 With the scaffold caps facing up, four male luer-to-thread fittings and four female 
luer-to-thread fittings were threaded onto the caps (Fig. 39). Custom O-rings were then 
placed into the outer caps to provide a seal between the inside of the outer cap and the 
bioreactor chamber. Caps were threaded into the stainless-steel outer caps, and oriented 
so that all eight barbs were aligned with each other.  
	  
Figure 39: Scaffold caps installed with their associated fittings. 	  
Once the scaffold cap and outer cap were now connected, scaffolds could be fitted 
onto one of the outer caps. Using the Qosina barbs and silk threaded sutures, the PLGA 
scaffolds were sutured tightly around the barbs (Fig. 40). Once secured, one end of the 
barb-scaffold-barb component was connected to the male luer-to-thread fittings and the 
other end to the male-to-male luer lock connectors (Fig. 41).  
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Figure 40: Scaffold sutured to two Qosina barbs ready to be installed into bioreactor. 
	  
Figure 41: Scaffold installation into bioreactor. 
4.3.2 Outer Cap Installation  
 After scaffold installation, the two outer caps were then ready to be inserted into 
the acrylic outer housing to construct the bioreactor. The outer caps were pushed into the 
outer housing until there was 1/8” of silicone still visible from the edges of the housing. 
Simultaneously, alignment of the end of the barbs and the male-to-male fittings was 
important so the scaffolds could be connected. Once aligned, scaffold barbs were secured 
by turning the male-to-male fittings counterclockwise, securing the luer lock connection.  
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4.3.3 Bioreactor Cap 
 The bioreactor cap was then placed over the outer housing window. The cap was 
centered over the window, as alignment of the cap was important to maintain a seal of the 
chamber. Once placed, the window was pressed firmly to assure that all surfaces of the 
silicone were touching the acrylic housing. Three stainless-steel hose clamps were then 
placed around the housing and cap to close the bioreactor and prevent leaking. Following 
this assembly, the rest of the tubing was connected to complete the system described 
below.  
4.3.4 Tubing & Media Reservoir 
 Once the bioreactor was assembled, tubing was connected to provide flow from 
the media reservoir, through the pump tubing, into the inlet of the bioreactor, through the 
outlet (transmurally or transluminally), and back into the media reservoir. Starting with 
the outlet of the media reservoir, tubing was connected the pump and then the inlet of the 
bioreactor. The outlet tubing of the bioreactor was then connected with the inlet tubing of 
the media reservoir, completing a cycle back to the outlet of the reservoir (Fig. 42).  
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Figure 42: Inlet Tubing: Connect one end of the inlet tubing to the outlet 
connection of the pump tubing (1). Then, connect the other end to the inlet of the 
bioreactor (2). 
Outlet Tubing: There are three ends in the outlet tubing. Connect one end to the 
outlet of the bioreactor (3), and another end should be connected to one of the 
transmural ports on the side of the bioreactor (4). The last end should be 
connected to the outlet port of the media reservoir (5). 
Pump Tubing: Connect the inlet connection of the pump tubing to the inlet port of 
the media reservoir (6). The outlet connection should be connected to the inlet 
tubing of the bioreactor. 
 
  
Assembly protocols for the tubing and media reservoir as well as the previous 
assembly processes mentioned above were further described in detail in Appendix D. As 
the assembly protocols were finalized, the system was ready to perform cellular testing to 
further evaluate the capabilities of the bioreactor.  
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Chapter 5: Cell Testing Methods, Results, & Discussion 
5.1 Introduction  
 Once the assembly process had been finalized and documented, the next step was 
to test the system with cells. Testing with cellular components progressed from non-
sterile tests, to sterile tests, and from single scaffold tests, to four scaffold tests. Each test 
further evaluated the capabilities and performance of the bioreactor, with a focus on 
aspects such as leaks, cell distribution, sterility, cell viability, and long-term cultivation. 
Single scaffold studies were presented as proof-of-concept studies and four-scaffold tests 
were designed to evaluate cell densities and cell distribution in proximal, middle, and 
distal regions of the scaffolds. “Proximal” refers to the region being closest to the inlet of 
the bioreactor, while “distal” refers to a region farthest away from the inlet. “Middle” was 
the region in between the two. Multiple-scaffold tests also investigated flow distribution 
between top, bottom, left, and right scaffold ports.  Fibroblasts were chosen as the cell 
type for all tests due to the ease of culture, maintenance, and lower cost compared to 
other cell types used in the lab. Methods for sterile or non-sterile, single scaffold, and 
multiple scaffold tests are outlined below. Detailed protocols of all tests can be referred 
to in Appendix D.  
5.2 Sterility Evaluation 
Contamination can be a result of microorganisms entering the bioreactor system. 
During cell culture, contamination typically does not become a problem until after the 
first twenty-four hours. Therefore, non-sterile studies were conducted in twenty-four 
hours or less. In order for the bioreactor to perform long-term culture, sterile conditions 
were necessary to recreate normal culture conditions such as pH. Bioreactor tests were 
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conducted using non-sterile for short-term studies or sterile techniques for longer-term 
studies. Non-sterile conditions presented information quickly, allowing quick assessment 
of the presence and the distribution of the cells on the scaffold. Assembly of the 
bioreactor was done outside of the laminar flow hood. After the bioreactor was then 
brought into the hood, bioreactor media was poured into the chamber, and conditioning 
media was poured into the media reservoir. The bioreactor pump tubing was then brought 
into the large incubator, where the pump would be installed. Pump installation involved 
securing the pump tubing into the CellMax pumping station. The bioreactor was then 
primed to allow all air to be expelled from the system (Fig. 43).  
	  
Figure 43: System primed before transmural flow. 	  
Once the system was primed, the bioreactor was ready for flow. Sterile 
experiments involved more restrictions in terms of handling compared to non-sterile 
setups. Bioreactor handling occurred inside the hood with the use of sterile gloves. 
Results are summarized in the table below indicating which protocols maintained 
sterility. Sterile protocols resulted in the most successful experiments across all types of 
testing. After standardizing protocols for using the bioreactor, single-scaffold evaluation 
was next to assess the presence of cells and cell distribution on a scaffold.   
 
	   63	  
Table VII: Evaluation of Sterile and Non-sterile protocols across all types of tests 
 Problems in 24 hour 
single-scaffold set-
up  
Problems in 7-day 
single-scaffold set-
up 
Problems in 7-day 
multi-scaffold set-
up. 
Non-Sterile Protocol Yes N/A N/A 
Sterile Protocol No No No 
 
5.3 Single-Scaffold Testing Methods & Results 
Single-scaffold testing allowed the assessment of the presence and distribution of 
cells and the ability of long-term culture of up to seven days. Both sterile and non-sterile 
experiments were conducted for single-scaffold tests. The first single single-scaffold test 
was a non-sterile twenty-four hour set-up. A twenty-four hour conditioning period was 
implemented to allow proteins in the media to radially stick onto the inner lumen of the 
scaffold prior to sodding of cells. The experiment involved one 100% confluent T75 flask 
of 3T3 fibroblast cells, providing around 3-4 million cells to the bioreactor. Pump 
settings maintained at a rate of 1ml/min or a shear stress of 1.4 dynes/cm2 [62]. At the end 
of the culture period, scaffolds were extracted and evaluated for cell presence and 
distributions using a Bisbenzimide (BBI) stain. Images were taken at 40X magnification 
at proximal, middle, and distal regions. Sterile single-scaffold testing followed the same 
protocol described in section 5.2 to obtain the qualitative assessment cell presence and 
distribution. Once data was collected for sterile twenty-four hour experiments, seven-day 
culture set-ups could be evaluated. Seven-day set-ups followed the same protocols as 
twenty-four hour experiments except for the addition of feeding schedules. For longer 
duration studies, a new conical of fibroblast media was given every other day until the 
conclusion of the test.  
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The non-sterile scaffold test resulted in contamination after cells were introduced 
into the bioreactor. The contamination caused discoloration of bioreactor and reservoir 
media (Fig. 44). The experiment had to be taken down and disassembled to be cleaned. 
All fittings were collected and soaked in bleach for twenty-four hours, while the acrylic 
housing and tubing were sent to EtO to be sterilized before any more experiments could 
be conducted. Sterile protocols were now used to avoid incidences such as these.  
	  
Figure 44: Contaminated bioreactor 7 hours after cells were introduced into the system. 
 
Results from using sterile protocols gave us BBI images of proximal, middle, and 
distal regions of the scaffold (Fig. 45). These images allowed us to assess consistency and 
distribution of cells. Contamination was not seen in any cases when sterile protocols were 
performed. Similar results were seen when performing seven-day culture experiments 
(Fig. 46). Single-scaffold tests showed that the bioreactor system could culture cells 
between acute and long-term studies. It was then necessary to perform multi-scaffold 
tests to assess cell distribution between all scaffolds.  
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Figure 45: BBI Images of single-scaffold short-term test, showing fibroblasts in proximal 
(top left), middle (top right), and distal regions (bottom). 
 
 
	  
Figure 46: BBI Images of single-scaffold long-term test, showing fibroblasts in proximal 
(top left), middle (top right), and distal region (bottom). 
5.4 Multiple-Scaffold Testing 
 Multiple-scaffold testing provided quantitative results as opposed to the 
qualitative results in single scaffold tests. Sterile procedures were used in these 
experiments, as long-term cultivation (seven days) was required for this stage of testing. 
Scaffolds were orientated in a square pattern with each position labeled as scaffold 1-4 
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(Fig. 47). Scaffolds 1 and 3 were used to analyze cell distribution from proximal to distal 
ends. However, the proximal end of scaffolds 2 and the distal end of scaffold 4 were used 
to run cell viability studies subsequently.  
	  
Figure 47: Scaffold configuration of four scaffolds. 
 
The bioreactor went through a twenty-four hour conditioning period under 
transmural flow prior to sodding of cells. Three T75 flasks of 3T3 fibroblasts grown at 
100% confluency were used to sod the scaffolds, tripling the amount used in single-
scaffold experiments. The pump setting was set to setting 1, giving a flow rate of 4 
mL/min or a shear stress of 1.4 dynes/cm2. Fibroblasts were fed according to the same 
schedule conducted during long-term single-scaffold tests. Cell distribution was assessed 
through each scaffold region including proximal, middle, and distal, as well as top, 
bottom, left, and right scaffolds. Cell densities were measured based on average number 
of cells per mm2 quantified for each region. Three images of each region, proximal, 
middle, and distal, were taken. Using the Ronchi Ruling, a slide with 150 vertical lines 
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per millimeter used to determine the size of the field, a conversion factor from pixels to 
millimeters was created. A box of known dimensions was then used to gain information 
on the number of cells inside the box, and three box counts were made per image (Fig. 
48).  
	  
Figure 48: Box created to count cells in each image to obtain cells/mm2. 
 
Cell densities were calculated per box resulting in number of cells per mm2. By using the 
raw data, finding the number of cells per mm2, taking the log of those cell densities, and 
averaging them, assuming the data follows a Poisson distribution, this corrected any lack 
of equality of spread. Performing a log transformation helped the data to be amenable for 
analysis of variance (ANOVA) procedures. Essentially averaging the log created a more 
normal distribution. Data preparation when conducting T-tests used the same technique. 
The T-tests were used to evaluate total cell number differences between top and bottom 
scaffolds. ANOVA tests assessed differences in regions of different scaffolds including 
proximal, middle, and distal. Tukey tests were used in association with ANOVA to figure 
out which variables were different.  
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After seven days of culture with no leaks or contamination, results showed that 
cells were still present on the inner lumen of the scaffold. These results were used to gain 
quantitative information regarding differences in cell distribution between the top, 
bottom, left, and right scaffolds. Statistical analysis evaluated differences between top 
and bottom, and differences in proximal, middle, and distal regions of each of the four 
scaffolds. BBI images displayed cell distribution in the three scaffold regions (Fig. 49). 
	  
Figure 49: BBI Image of bottom scaffold displaying proximal (top left), middle (top 
right), and distal (bottom center). 	  
Results of the two-tailed T-test evaluating total cell number per scaffold between top and 
bottom scaffolds showed a p-value of .0036, showing that there was a statistical 
difference in cell density between the top and bottom scaffolds. An ANOVA test used to 
test differences between regions in the top and bottom scaffolds resulted with a p-value of 
0.0355, further assessing statistical difference in the cell density between various regions 
of the scaffolds. Finally, a Tukey test indicated no differences between various regions of 
the scaffold.  
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 ANOVA procedures were also used to test differences between each proximal 
region for all scaffolds resulting with a p-value of less than 0.0001, showing statistical 
difference in the proximal regions of all the scaffolds. A Tukey test was used to 
determine which was different (Table VIII). The test indicated that scaffold 3 and 4 were 
not different from each other, but both were different from scaffold 1.  
 
Table VIII: Tukey test evaluating which proximal region is different. The column labeled 
“Mean” refers to the average log of the cellular densities for the proximal regions.  
Level        Mean 
4 A        6.30 
3 A        6.04 
1   B      5.51 
 
ANOVA testing on middle regions resulted with a p-value of 0.0013, indicating 
that there were statistical differences in the middle regions of all the scaffolds. A Tukey 
test was utilized to see which middle region was different from the others (Table IX). The 
results showed that groups with letter that did not overlap were statistically different.  
Another ANOVA meant to investigate differences between distal regions of different 
scaffolds produced a p-value of 0.8567, showing no statistical differences between the 
distal regions.  
 
Table IX: Tukey test evaluating which middle region is different. The column labeled 
“Mean” refers to the average log of the cellular densities for the middle regions.  
1        Mean 
3  A       6.0878919 
4  A B     5.8386302 
1    B     5.2678068 
2    B     5.2503754 
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The results obtained from the T-test when evaluating total cell number for both 
top and bottom scaffolds, indicated that the bottom scaffold had more cells compared to 
the top (Fig. 50). This could be a result of slow injection rates, resulting in flow toward 
the path of least resistance. By implementing an additional sodding procedure to the 
bioreactor, this solution would assess the uneven distribution between the top and bottom 
scaffolds. Although the Tukey test did not show differences between regions, the 
ANOVA test did show a difference. This occurred based on the Tukey multiple 
comparison tests only comparing means, and that the overall p-value produced by the 
ANOVA does not guarantee that the Tukey test will find a significant difference [66]. 
	  
Figure 50: Graph displaying differences in total cell number on scaffold between top and 
bottom scaffold arrangement. 
 
The ANOVA test that evaluated proximal regions for all scaffolds indicated that 
there was a difference. The corresponding Tukey test showed that top (scaffold 1) and 
bottom (scaffold 3 & 4) proximal regions were different, however no differences could be 
seen between left and right bottom proximal regions. ANOVA testing of middle regions 
of the scaffolds showed that there was a difference across all scaffolds. The Tukey tests 
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indicated that there was only a difference between the top and bottom on scaffold 3. The 
middle region of scaffold 4 showed no difference between the two top scaffolds. There 
were no differences between left and right scaffolds as well. Lastly, ANOVA testing 
distal regions across all scaffolds indicated that there were no differences (Fig. 51). In the 
end, results from the proximal region of scaffold 2 and the distal region of scaffold 4 
were excluded from this study and were used in the results of cell viability described in 
the next section.  
	  
Figure 51: A graph displaying average cell densities versus scaffold and scaffold region. 
Letters are results of a Tukey tests indicating similarities and differences across scaffold 
regions. Proximal and distal regions of scaffolds 2 and 4 were excluded as their results 
were used in cell viability testing.  
 
A trend showing an increase in average cell density from top to bottom scaffolds 
at the proximal end to the distal end was observed, however there are no differences 
between regions at the distal end. This may be a result from sodding the cells from one 
side of the bioreactor. Including an alternative cell induction port to sod cells in a 
different location would contribute to provide uniform distribution from proximal to 
distal ends of the scaffolds.   
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5.5 Cell Viability Testing 
 Evaluation of cell viability was necessary to illustrate that the system could 
cultivate a living tissue construct and determine if EtO sterilization was harmful to cells. 
Cell viability testing used sterile protocols as well as single and multiple-scaffold tests. 
Culture duration was seven days serving as a good indicator if cells were harmed by EtO 
residue. Cell culture requirements for both single and multi-scaffold set-ups previously 
mentioned were used in cell viability testing. A Single-scaffold set-up was first used to 
assess viability. Multi-scaffold set-ups were used to obtain more cells to analyze. Using 
the cell viability protocol created by Chris Miracle [69], once the scaffold was extracted 
from the bioreactor, cells were trypsinized from the scaffold and assessed using either 
trypan blue or cell viability assay kit provided by Invitrogen (L3224). Trypan blue enters 
the cells based on its membrane integrity, resulting in live cells with a blue outline around 
their perimeter and a clear center, and dead cells colored blue. The cell viability assay kit 
stains living cells green and dead cells red, and utilizes a hemocytometer to perform 
counts. Protocols for cell viability tests are included in Appendix D. 
 Cell viability results could not be obtained in single-scaffold tests due to the small 
number of cells that could possibly be extracted from the scaffold. When multi-scaffold 
set-ups were used, results provided cell viability percentages. Table X shows the different 
measurements taken from the cell counter (Nexcelcom Cellometer Auto T4). As some 
quadrants were absent of cells, an automated count could not be obtained and manual 
counts were made. No dead cells were found in any of the quadrants of the cell counter 
slide. To verify these results, images taken on the fluorescent microscope indicated living 
and dead cells (Fig. 52).  
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Table X: Table showing results obtained from cell counter. All counts resulted in 100% 
viability with no visual indication of dead cells in any of the quadrants of the cell counter 
slide. 
Cell Viability  Total Cell Concentration (Cells/ml) 
100% 8.8 X 104 
100% 8.5 X 104 
100% 9.9 X 104 
100% 1.3 X 105 
100% 3.9 X 104 
 
 
	  
Figure 52: One set of images from fluorescent microscope indicating no dead cells 
observed. The cell highlighted inside the red box indicates the living cell found in that 
region of the hemocytometer. 
 
Evaluation of the cell viability studies concluded that EtO residue was not harmful to 
cells and cell viability in long-term culture was achievable. The results obtained from the 
cell counter cannot conclusively show that there was 100% cell viability. Cell viability is 
a percentage that requires both live and dead cell counts, and as there were no visible 
dead cells, the percentage reflects only the live cells counted. Additional testing is 
required to fully verify the 100% cell viability figure. Although few living cells were 
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found on the hemocytometer, no dead cells were observed. The small amount of cells 
present on the hemocytometer may have been a result of the design of the experiment: 
when assessing cell viability, only halves of scaffolds were used. Thus, when the cells 
were trypsinized there may have been a low number of cells obtained, resulting in a small 
pellet when centrifuged or accidently aspirated when removing the supernatant. However, 
results did show the presence of living cells and absence of dead cells. From these results, 
pre-installation of scaffolds prior to sterilization was safe to perform, and allowed for a 
decreased set-up time of fifteen minutes in the hood. The studies performed above in this 
segment of work illustrated that the bioreactor could perform as well as the other culture 
system seen in the laboratory. The bioreactor’s ability to perform these cellular tests 
allows the introduction of native components of the BBB in future testing.  
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Chapter 6: Final Discussion, Future Work, Limitations, & 
Conclusion 
6.1 Final Discussion 
Overall, the design of the bioreactor was optimized to display ease of use in 
assembly, sterilization, conditioning, and culture. Assembly was developed so that the 
user had no complications when inserting the outer caps into the housing. The method of 
pre-scaffold installation allowed more space for users to work with the bioreactor, 
provided less concern about using aseptic technique, and translated to easier set up 
procedures when conditioning the bioreactor. This method led to the protocol of never 
having to interact with the internal components of the bioreactor once sterilized, 
sustaining sterile conditions and creating easier protocols for use.  
Placing the bioreactor in one package allowed the system to be fully assembled 
and allowed the system to require less time in the hood. After determining that 
contamination can occur when tubing, scaffolds, and components are not sterilized in 
non-sterile 24-hour experiments, sterile procedures were chosen to be apart of all 
experimental set-ups when working with this bioreactor system. As a result, there was 
only one contamination occurrence out of all the experiments conducted when testing the 
system.  
The flow rates measured and used in the bioreactor system were similar to rates 
measured in literature [53,57,60]. For example, Cucullo et al., showed that shear stress 
maximum in blood capillaries was about 5 dynes/cm2 [53]. All of the experiments were 
well under this estimated maximum shear stress. During testing of a new DIV-BBB, 
Cucullo discussed that the pumping mechanism was capable of generating flow levels 
from 1 to 50 ml/min with associated shear stresses of 1-200 dynes/cm2 [58]. These ranges 
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were achieved with the system presented here as well. Compared to the flow rates 
measured in Mr. Brandon’s project, similar flow rates were achieved providing suitable 
ranges of shear stresses for future testing on the bioreactor. 
The bioreactor designed in this thesis aimed to improve upon the limitations of 
the CellMax system, including the destruction of the CellMax bioreactors and the 
difficulty of extracting scaffolds. The bioreactor was designed to be reusable, avoiding 
the need to purchase multiple bioreactors for each experiment. The bioreactor cap 
allowed access into the bioreactor chamber, preserving the bioreactor during scaffold 
extraction. The use of an acrylic housing allowed increased visibility into the bioreactor 
chamber to monitor the scaffolds and the media during culture. Although, the size and 
weight of the bioreactor were significantly larger than the CellMax system, the bioreactor 
was able to fit into the allotted space in the large incubator.  
Compared to the Lock N Lock bioreactors, the bioreactor used for BBB testing 
displayed both favorable and non-favorable attributes including assembly processes, 
chamber access, and sterilization procedures. The BBB bioreactor consists of more 
components for the users to construct and requires larger packaging for sterilization. The 
Lock N Lock system consists of a chamber with tubing permanently installed simplifying 
assembly of the system to connecting the media reservoir and Tupperware cap 
connections. Assembly time was shorter for the Lock N Lock system compared to the 
BBB bioreactor. Packaging the BBB bioreactor for sterilization requires the system be 
fully assembled and partially closed, while the Lock N Lock bioreactors require separate 
packaging and sterilization procedures for system sterilization. Chamber access was more 
time intensive in the BBB bioreactors as the hose clamps were removed before opening 
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the bioreactor cap, compared to the Lock N Lock bioreactors that required flipping the 
clamps connected to the cap to access the bioreactor chamber. This eases the process of 
loading bioreactor media into the bioreactor chamber of the Lock N Locks, and is 
accomplished by simply pouring media into the bioreactor chamber of the Lock N Locks, 
instead of using a glass funnel to pour the media into the chamber. The glass funnel 
technique does require more time to fill the chamber, however was effective in 
maintaining sterility of the system. The BBB bioreactor’s ability to culture more 
scaffolds at one time can easily be implemented into the Lock N Lock bioreactor with the 
installation of holes for additional ports. Although the BBB bioreactor can only match 
some attributes of the Lock N Lock bioreactors, future work can potentially increase the 
performance of the bioreactor developed in this thesis. 
6.2 Future Work & Limitations 
To alleviate the problem of non-uniform distribution between top and bottom 
scaffolds, sodding of cells can also occur when flipping the bioreactor over so that the 
bioreactor cap is facing down. By introducing a three-way stop cock on the outlet and 
sodding cells from both sides we could possibly alleviate the problem of uneven 
distribution at the proximal sides. Additional cell viability tests must be conducted to 
further evaluate cell viability. The protocol explained (in Section 5.5) can be used to 
repeat the test, but an additional step of saving the scaffold to observe if all the cells were 
taken off using BBI should be included. An alternative test could be a static cell viability 
test with the use of well plates to investigate cell viability on a scaffold. This approach 
alleviates the need to extract cells from the scaffold. By placing a sample of PLGA at the 
bottom of a well plate and seeding cells onto the scaffold, the Invitrogen Cell Viability 
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Assay can be used to view the cell under the fluorescent microscope after 7 days of 
culture.  Introduction of ECs and glial cells can now be implemented to characterize the 
interactions between the two cell types. Development of protocols for introducing two 
cell types into the bioreactor must be made. The creation of smaller barbs could allow for 
the use of smaller scaffolds, which would provide a more accurate culture environment. 
The work of two undergraduates, Matt Rogers and Nathan Ferrier, created barb-to-thread 
fittings that would allow for the use of 1mm inner diameter scaffolds in future testing of 
the bioreactor. However as we scale down even further in size, difficulty increases in 
protocols such as scaffold cutting during analysis. An assessment must be made as to 
how protocols for this bioreactor will change as we try to improve upon the recapitulation 
of the BBB’s environment. Concerns such as change in flow rate, scale of the pumping 
mechanism, culture protocols, and scale of associated components of the bioreactor are 
brought to attention as well when thinking of introducing more physiological conditions. 
Using smaller diameter scaffolds will require smaller scale barbs to connect them to. 
Flow rates that use these smaller barbs and scaffolds will need to be characterized to 
maintain the shear rate range required for BBB research. If the pump currently being used 
is not compatible with these smaller barbs and scaffolds to produce these shear ranges, 
then a new pump will need to be acquired for future tests. Culture protocols might be 
changed due to the fragility of the scaffolds at such low diameters.  
One limitation of this thesis is using a protocol that relies on the use of other 
departments such as the Animal Science Department for their sterilization procedures. 
The fact that experiments were constrained to availability for sterilization increases the 
length of the experiment as a whole. Obtaining an EtO sterilizer for Cal Poly’s Tissue 
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Engineering lab would allow tests to be conducted at any time. The procedure of 
trypsinizing the scaffolds during cell viability tests was challenging, limiting the number 
of cells that could be extracted and viewed under the fluorescent scope. When dealing 
with cells from only a half of a scaffold, there is only a small volume of cells that can be 
extracted. There was extreme caution not to aspirate the pellet after centrifugation, as 
well as not to dilute the pellet during resuspension. By implementing the additional cell 
viability test mentioned above, the effect of EtO residue on cells could be further 
explored. Another limitation was the weight of the bioreactor. Although stainless steel 
was an optimal material to be used in the design of the bioreactor, the weight did cause 
some accidents when dropped or ripped during packaging. Using a different material may 
be a solution to reduce the weight of the system, however, durability was chosen over 
weight to maintain reusability.  
6.3 Conclusion 
The work accomplished in this thesis aimed to build upon the second aim in Mr. 
Brandon’s project [62]. The development and creation of an in-house bioreactor was 
completed to dramatically reduce costs in testing in the lab, to provide easy access to 
scaffolds, and to avoid destruction of the bioreactor for assessment and analysis as 
reiterated in the future work first presented by Mr. Brandon [62]. The aims, design 
processes, methods, and results of the BBB bioreactor have been discussed in detail 
throughout this thesis. The creation of this bioreactor has the potential to contribute in the 
investigations of the BBB and to aid the pharmaceutical industry in the over one billion 
dollar drug discovery process [70]. The BBB bioreactor provides an in-house, reusable 
model to recapitulate the BBB compared to previous commercial products. The design of 
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the bioreactor helps users to easily assemble, culture, and analyze tissue constructs grown 
to further increase progress in research and industry. As researchers continue to search 
for robust systems to recreate physiological environments, this thesis can provide a basis 
to further develop and improve upon models of the BBB. 
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Appendix A – Abbreviations  	  
AIDS – Acquired Immune Deficiency Syndrome 
AJs – Adherens Junction Proteins 
ANOVA – Analysis of Variance 
BBB – Blood-Brain Barrier 
BBI – Bisbenzimide  
BMVEC – Brain Microvascular Endothelial Cells 
BUI – Brain Uptake Index 
CNS – Central Nervous System 
CSF – Cerebral-Spinal Fluid 
DIV-BBB – Dynamic In Vitro Model of the Blood-Brain Barrier 
ECs – Endothelial Cells 
ePTFE – Expanded Polytetrafluoroethylene 
EtO – Ethylene Oxide 
HTS – High Throughput Screening 
NVU – Neurovascular Unit 
PET – Positron Emission Tomography 
PLGA – Poly(lactic-co-glycolic acid) 
QSAR – Quantitative Structure Activity Relationship 
TEER – Trans-endothelial electrical resistance 
TJs – Tight Junctions 
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Appendix B – Parts Information and Design Drawings  	  
 
Component Description Company Website Part 
Num
ber 
Outer 
Housing 
Scratch-Resistant Clear  
Cast Acrylic Tube,  
3” OD X 2-5/8” ID,  
1’ Length 
 
 
McMaster-Carr www.mcmaster.com 
 
 
8486
K463 
Outer Caps 2.497” DIA Outer Caps Atech 
Manufacturing 
 N/A 
Bioreactor 
Cap 
Scratch-Resistant Clear 
Cast Acrylic Tube, 3-
1/2” OD X 3-1/8” ID, 1’ 
Length 
McMaster-Carr www.mcmaster.com 8486
K473 
Silicon Sheet Super-Soft Silicone 
Rubber, Adhesive Back, 
1/16” Thick, 12” X12”, 
20A Durometer 
McMaster-Carr www.mcmaster.com 9010
K422 
Internal O-
ring 
Silicone Sealing Washer 
1” Screw Size, 2” OD, 
.093” Thick, Packs of 10 
McMaster-Carr www.mcmaster.com 9960
4A13
1 
Custom 
Square O-
ring 
Super-Soft Silicone 
Rubber, Plain Back, 
3/16” Thick, 6” X 6”, 
20A Durometer 
McMaster-Carr www.mcmaster.com 9010
K842 
Scaffold Cap 1.75” DIA Scaffold 
Caps 
Atech 
Manufacturing 
 N/A 
Outlet barbs Sanitary White PVDF 
Sngl-Barbed Tube 
Fitting Adapter for 1/4” 
Tube ID X 1/4” NPT 
Male Pipe 
McMaster-Carr www.mcmaster.com 
 
 
 
5305
5K21
3 
Hose Clamps Worm-Drive Hose & Tube 
 Clamp with Thumb 
 Screw, 2-9/16” to  
3-1/2” Clamp Diameter  
Range, 9/16” Band  
Width, Packs of 5 
Th 
 
 
McMaster-Carr www.mcmaster.com 5362
K24 
Female Luer-
Thread 
Fitting 
Female Luer x 10-32 
UNF thread, PP, 25/pk 
Cole-Parmer www.coleparmer.co
m 
4550
0-60 
Male Luer- Male Luer Integral Lock Value Plastic www.valueplastic.co XMT
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Thread 
Fitting 
Ring to 10-32 Special 
Tapered Thread, White 
Nylong 
m LL-1 
Qosina Barbs Female Luer Lock to 
Barb Connector, Fits 
1/32” ID tubing 
Qosina www.qosina.com 1173
3 
Male-to-
Male Fitting 
Male-to-Male Luer 
Connector with One 
Rotating Collar 
Qosina www.qosina.com 1766
4 
Female-to-
Female 
Coupler 
Female Luer Thread 
Style Coupler 
Value Plastics www.valueplastics.c
om 
FTLL
C-1 
 
Male-to-Barb 
fitting 
Male Luer Integral Lock 
Ring to 200 Series Barb, 
1/8” (3.2 mm) ID 
Tubing, White Nylon 
 
Value Plastics www.valueplastics.c
om 
 
MTL
L230-
1 
Female Luer-
to-Barb 
Female Luer Thread 
Style to 200 Series Barb, 
1/8” (3.2 mm) ID 
Tubing, White Nylon 
 
Value Plastics www.valueplastics.c
om 
FTLL
230-1 
Y-Connector Y-Connector with 200 
Series Barbs, 1/8” (3.2 
mm) ID Tubing, White 
Nylon 
Value Plastics www.valueplatics.co
m 
Y230
-1 
End Cap Male Luer Integral Lock 
Ring Plug, Closed at 
Grip, White Nylon 
 
Value Plastics www.valueplastics.c
om 
LP4-
1 
3-Way Stop 
Cock 
Three-Way Stopcock, 2 
Capped Female Luer 
Thread Style & Capped 
Male Luer Lock, 
Polycarbonate Body w/ 
Polyethylene Handle 
 
Value Plastics www.valueplastics.c
om 
VPB1
0000
79N 
1-Way Stop 
Cock 
One-Way Stopcock, 
Capped Male Luer Lock 
to Capped Female Luer 
Thread Style, 
Value Plastics www.valueplastics.c
om 
 
 
VP45
5980 
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Polycarbonate Body w/ 
Polyethylene Handle 
 
Tubing Tygon Silicone Tubing 
1/8" ID x 1/4" OD 
 
Cole Parmer www.coleparmer.co
m 
WU-
9570
2-06 
Gas 
Permeable 
Tubing 
Tygon Silicone Tubing 
3350 1/8 x 3/16 
Cole Parmer www.coleparmer.co
m 
EW-
9570
2-05 
50 ml 
Conical 
BD FalconTM 50 ml 
Conical-Bottom 
Polypropylene Tube 
BD  www.bd.com 3520
98 
Loctite 4011 Prism 4011 Medical 
Glue, 20 Gm Net 
Weight Bottle 
McMaster-Carr www.mcmaster.com 
 
1818
A4 
Loctite 
Solvent 
LOCTITE 768 X-NMS 
Clean Up Solvent For 
Instant Adhesive 52 ml 
 
Ellsworth www.ellsworth.com 7682
0 
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Appendix C – Barb Testing  
  
Barb testing was the first cellular based assessment performed using the barbs 
used in BBB bioreactor. The barb testing investigated whether the smaller scale barb and 
scaffold installation technique functioned properly. In addition, the barbs were also 
evaluated for compatibility in the Tupperware bioreactors. The Tupperware bioreactors 
were used prior to the BBB bioreactor, since validation that the barb-scaffold-barb 
configuration worked in an existing bioreactor system would help explain the BBB 
bioreactor’s efficiency. Using the non-sterile set-up protocol, a single 3.5cm scaffold 
sutured to Qosina barbs was fitted into the bioreactor secured by rotating male luer locks. 
Then bioreactor media was poured into the chamber, while conditioning media was 
inserted into the reservoir. Once primed, the appropriate pump setting was selected and 
transmural flow conditions were operated for twenty-four hours. Transmural flow 
allowed radial dispersion of fluid away from the scaffold and out through the transmural 
outlet. These proteins would later facilitate the growth of cellular components within the 
scaffold. After twenty-four hours of conditioning, fibroblasts conditioned in one T75 
flask up to 90-100% confluency was obtained and injected into the cell induction port. 
Once the cells were in the system, transmural flow was continued to allow the cells to be 
pushed radially onto the inner lumen of the scaffold for one hour. After an hour, flow was 
switched to transluminal flow for the remainder of the 24-hour experiment. The large 
incubator was set to 5% CO2 and 37oC, replicating the physiological environment of the 
human body.  
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 The barb testing experiments were assessed using BBI and Scanning Electron 
Microscope (SEM) images. These images were used for qualitative evaluation in a short 
proof-of-concept study. BBI images display fibroblast nuclei fluorescing and distribution 
of cells throughout regions of the scaffold. While SEM images enable us to identify cell 
coverage on the inner lumen of the scaffold, along with the perception of the depth.  
	  
BBI images showing presence of cells on scaffold proximally (top left), middle (top 
right), and distally (bottom center). 
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SEM Image of scaffold lumen imaged at 180X magnification. Designation between cell 
coverage and bare scaffold can be seen due to blade scrape when cutting the scaffold. 	  
Results from barb testing showed that the barb component of the bioreactor functioned in 
the Tupperware bioreactors regularly used in the lab. Accordingly, the barbs were 
expected to function effectively in the BBB bioreactor. Barb testing provided qualitative 
information that demonstrated good distribution of cells across all regions of the scaffold. 
The positive results from barb testing were translated to single-scaffold experiments in 
the BBB bioreactor; again displaying the presence of cells across proximal, middle, and 
distal regions of the scaffold. This showed that the BBB bioreactor was able to produce 
similar results to the Tupperware bioreactor used in the lab, matching performance and 
ease of use. These proof-of-concept studies served as a preliminary baseline for the multi-
scaffold experiments that would test the true function of the designed bioreactor and its 
ability for long-term culture. 	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Appendix D – Protocols  
 
Assembly Protocol 
 
Component Company Part Number Quantity 
Outer Housing McMaster-Carr 8486K463 1 
Outer Caps Atech 
Manufacturing 
N/A 2 
Bioreactor Cap McMaster-Carr 8486K473 1 
Internal O-ring McMaster-Carr 99604A131 2 
Custom Square 
O-ring 
McMaster-Carr 9010K842 2 
Scaffold Cap Atech 
Manufacturing 
N/A 2 
Outlet barbs McMaster-Carr 53055K213 2 
Hose Clamps McMaster-Carr 5362K24 3 
Female Luer-
Thread Fitting 
Cole-Parmer 45500-60 4 
Male Luer-
Thread Fitting 
Value Plastic XMTLL-1 4 
Qosina Barbs Qosina 11733 8 
Male-to-Male 
Fitting 
Qosina 17664 4 
Female-to-
Female Coupler 
Value Plastics FTLLC-1 
 
1 
Male-to-Barb 
fitting 
Value Plastics MTLL230-1 6 
Female Luer-to-
Barb 
Value Plastics FTLL230-1 4 
Y-Connector Value Plastics Y230-1 1 
End Cap Value Plastics LP4-1 2 
3-Way Stop 
Cock 
Value Plastics VPB1000079N 1 
1-Way Stop 
Cock 
Value Plastics VP455980 2 
Tubing Cole Parmer WU-95702-06 5 
Gas Permeable 
Tubing 
Cole Parmer EW-95702-05 2 
50 ml Conical BD  352098 1 
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____1. Custom O-ring: Place custom square O-ring into O-ring 
groove located on the outer caps. Be sure not to 
excessively compress O-ring into groove, allow it to sit to 
allow the O-ring to uniformly wrap around the outer cap. 
Excessive compression will allow risk of leaking from 
the ends of the bioreactor 
 
 
____2. Scaffold Cap 1: Based on the number of scaffolds being 
used in the experiment, connect luer to thread fittings onto 
scaffold cap. Then connect male-to-male couplings to 
scaffold cap.	   
 
 
 
 
 
 
 
 
 
 
 
____3. Scaffold Cap 2: Connect Value Plastic fittings.  
 
 
 
 
 
 
 
____4. Place internal O-rings into outer cap. 
 
 
 
 
 
 
____5. Thread scaffold caps to outer caps. 
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____6. Scaffold Installation: (Refer to 
Scaffold Assembly Protocol for 
instructions) Take scaffold and 
attach to stationary end. 
 
 
 
 
 
 
____7. Push both outer caps into outer housing. Make sure to 
leave at least 1/8” of silicon gasket material hanging out 
of the outer housing.  
 
 
 
 
 
 
 
 
 
 
 
____8. Connect the other end of the scaffold to the 
fittings on the other outer cap. Make sure that the 
scaffolds are secured in the male-to-male fitting.  
 
 
 
 
____9. Position bioreactor cap so that it is centered on the 
window.  
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____10. Apply hose clamps around both left and right edges 
and middle of the bioreactor cap. 
 
 
 
 
 
 
 
 
 
 
 
 
____11. Attach outlet barbs to each of the outer 
caps 
 
 
 
 
 
 
 
 
 
____12. Tubing: Attach inlet, outlet, and pump tubing 
Inlet Tubing: connect one end of the inlet tubing to the outlet connection of the 
pump tubing (1). Then connect the other end to the inlet of the bioreactor (2). 
Outlet Tubing: There are three ends in the outlet tubing. Connect one end to the 
outlet of the bioreactor (3), another end should be connected to one of the 
transmural ports on the side of the bioreactor (4). The last end should be 
connected to the outlet port of the media reservoir (5).  
Pump Tubing: Connect the inlet connection of the pump tubing to the inlet port of 
the media reservoir (6). The outlet connection should be connected to the inlet 
tubing of the bioreactor.  
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____13. Glass Funnel: 
Disconnect the transmural 
tubing at the Y-connector 
barb and slide the tubing onto 
the end of the glass funnel.  
 
 
 
 
 
 
 
 
 
____14. Be sure to leave one transmural port 
along with the bioreactor cap port open to 
allow EtO gas entry into the bioreactor (if a 
sterile set-up is required). If this is a non-
sterile set up, close both ports with end caps.  
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Scaffold Assembly Protocol 
 
Component Company Part Number Quantity  
Qosina Barbs Qosina 11733 2 (per scaffold) 
Silk-Suture Thread   Depends on # of 
scaffold 
PLGA Scaffold Cal Poly N/A Depends on 
experiment 
requirements 
 
1. Cut PLGA scaffold to 
1.6” in length. Be sure 
not to crush scaffold 
lumen or deform the 
scaffold (beware of 
kinks). 
 
2. Slip scaffold into one Qosina barb 
and suture using three-knots to 
fully secure scaffold tightly onto 
barb. Repeat process to secure the 
other end to finish scaffold 
assembly. 
 
 
 
3. With the secured scaffold on the two Quosina barbs, the scaffold will now be 
ready to be inserted into the bioreactor during the Assembly Protocol.  
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Sterile Experiment Protocol 
 
Duration: 24 hours or 7-Days 
Scaffold: PLGA 
Cell Type: 3T3 Fibroblast 
 
Preparation 1-week prior to set up 
 
_____1. Determine target number of cells and passage schedules.  
_____2. Thaw cells. 
_____3. Package and gas 
sterilize bioreactor 
system. 
 
 
 
 
 
 
 
 
 
 
_____4. Prepare bioreactor 
media. 
_____5. Prepare conditioning media.  
 
Set-up day: bioreactor conditioning  
 
_____6. Place packaged bioreactor on 
the right side of the hood. 
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_____7. Peel back blue film 
opening the package to the 
right. 
 
 
 
 
 
 
 
  
_____8. Locate the glass funnel used to insert bioreactor media into the bioreactor 
chamber.  
_____9. Proceed to pour bioreactor 
media into bioreactor chamber. Be 
sure not to pass hands over 
exposed fittings (Y-connector 
barb) or ports.  
 
 
 
 
 
_____10. When bioreactor media fully 
submerges all fittings, disconnect 
the glass funnel from tubing and 
reconnect the tubing back to the Y-
connector barb.  
 
 
 
 
 
_____11. Fill media reservoir with 50 ml of conditioning media. Prepare another 50 
ml conical with conditioning media 
 
Preparing the large incubator 
 
_____12. Spray down area being used. Careful not to interfere other culture set-ups 
that are currently being done.  
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_____13. Spray down pumping system 
and place into incubator. 
 
 
 
 
 
 
_____14. Bring the bioreactor, pump 
tubing, and media reservoir 
into large incubator. 
 
 
 
 
 
 
_____15. Turn pump to setting 1 to 
prime the bioreactor letting all the air out of the system.  
_____16. Watch media reservoir level to make sure that air is not being pumped. If 
media level is low during priming of the system, replace the 50 mL conical 
with more conditioning media.  
_____17. Once primed, turn off transluminal flow by switching the one-way 
stopcock perpendicular to the path of flow.  
_____18. Maintain transmural flow for 24 hours.  
_____19. Close incubator and set CO2 levels back to 5% 
 
 
Preparation for sodding cells 
 
_____20. Once cells have been 
trypsinized and 
deactivated with culture 
media transfer cells 
suspension into 1 trough. 
Prepare another trough 
full of culture media to 
chase the cell suspension. 
Be careful not to pass 
your hands over any part 
of the trough.  
 
 
_____21. Use a 10 mL syringe to sod the 
cells into the bioreactor.   
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_____22. When both cell syringe and chase media syringe is ready. Open the 
incubator and stop the pump. 
_____23.  Syringe cell contents 
slowly into the induction 
port of the three-way 
stopcock. Be sure to stop 
back flow by switch the off 
position back to the pump 
tubing. Close induction port 
once finished with 
injection.  
 
 
 
 
 
  
_____24. Syringe chase media through the same process as the previous syringe. 
Close induction port once finished with injection.  
_____25. Turn pump back on to setting 1.  
_____26. Allow transmural flow for 1 hour.  
_____27. After the hour, open the incubator, turn off pump, and switch from 
transmural to transluminal for the duration of the experiment.  
_____28. Maintain flow conditions at setting 1 for the duration of the experiment.   
_____29. Close incubator and set CO2 levels back to 5% 
 
 
For 7-Day Cultures 
 
_____30. Replace culture media every other day once cells are sodded into the 
system.  
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Bioreactor Take Down Protocol 
 
_____1. Close CO2 
tank prior to 
opening the large 
incubator.  
_____2. Using hose 
clamps and switch-
valves located on 
one- and three-way 
stop cocks, close off 
flow at the inlet 
tubing-pump tubing 
interface and at the 
inlet connection of 
the pump tubing and 
the inlet port of the 
media reservoir. 
This will allow detachment of the bioreactor from the pump tubing and allows the 
user to bring the bioreactor and media reservoir to the sink. Red arrows indicate 
areas that need to be clamped or one-way valves that need to be switched to stop 
flow. 
 
_____3. Scaffold Retrieval: The user can retrieve the scaffold(s) either using a 
razor blade to cut the scaffold out of the bioreactor, or by draining the bioreactor 
fluid from the bioreactor 
chamber and disconnect one of 
the of scaffold ends from the 
outer cap. This will allow the 
user to disconnect both outer 
caps from the outer housing 
and remove the scaffolds while 
intact on the Quosina barbs.  
 
 
 
 
 
_____4. Once scaffolds are removed, drain all bioreactor and cell media from 
tubing, outer caps, and pump tubing, down the sink. Be sure to chase with bleach.  
_____5. Rinse all components with water and place all small fittings into a small 
beaker with mili-Q water over night.  
_____6. Let larger components including outer caps, scaffold caps, inlet and outlet 
tubing, and outer housing to dry on the lab bench over night.   
_____7. Pump water through the pump tubing several times and then allow air to 
be pumped so that tubing can be dried over night.  
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Cell Viability Protocol Single-Scaffold Set-Up 
 
_____1. Take bioreactor out of incubator 
_____2. Be sure CO2 tank is off 
_____3. Place in sink and drain transmural fluid  
_____4. Unscrew scaffold from end caps and remove scaffold from bioreactor 
_____5. Cut scaffold 
horizontally through the 
diameter of the scaffold. One 
half goes to 2 ml of formalin 
15 minutes. Another half 
goes into 3 ml of trypsin 6-7 
minutes. 
 
 
 
 
 
 
Scaffold in formalin 
 
_____6. Extract scaffold from formalin and remove from barbs.  
_____7. Cut scaffold in half longitudinally. 
_____8. Wash in PBS twice. 
_____9. Put in BBI Solution for 25 minutes.  
Make BBI solution in a 15 ml conical (wrapped in foil). Use small tube of stock solution 
and dilute 1:1000 with milli-Q water (10 µL stock solution in 10 mL water). Take 
scaffold and place it into 15 ml conical of BBI solution for 25 minutes.  
 
Scaffold in trypsin 
 
_____10.  Place scaffold in 3 ml of trypsin for 6-7 minutes. Agitate and flush lumen 
using pipette. 
_____11.  Deactivate with 3 ml of fibroblast media. 
_____12.  Flush lumen to get all cells out. 
_____13.  Remove scaffold and dispose in biohazard bin.  
_____14.  Spin down at 1000 rpm for 5 minutes. 
_____15.  Aspirate the supernatant and re-suspend the cell pellet in 0.5 mL of 
fibroblast media. 
_____16.  Place 150 𝜇l cell solution 50 𝜇l of trypan blue. 
_____17.  Place 20 𝜇l into cellometer slide and view.  
 
Imaging 
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_____18.  BBI: Turret position 4, FW1 position 1, FW2 position 1. 
_____19.  Trypan blue: follow cellometer directions in 209a.  
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Cell Viability Protocol Multi-Scaffold Set-Up 
 
Scaffolds: 4 
 
_____1. Take bioreactor out of incubator 
_____2. Be sure CO2 tank is off 
_____3. Place in sink and drain transmural fluid  
_____4. Unscrew scaffold from end caps and remove scaffold from bioreactor 
_____5. Transfer as many intact scaffolds in formalin or trypsin.  
_____6. Scaffold should be in a 15 mL conical of trypsin for 6-7 minutes.  
_____7. Scaffold should be in a 15 mL conical of formalin for 15 minutes.  
 
Scaffold in formalin 
 
_____8. Extract scaffold from formalin and remove from barbs.  
_____9. Cut scaffold in half longitudinally. 
_____10. Wash in PBS twice. 
_____11. Place in BBI solution.  
Make BBI solution in a 15 ml conical (wrapped in foil). Use small tube of stock solution 
and dilute 1:1000 with milli-Q water (10 µL stock solution in 10 mL water). Mix by 
inverting. 
_____12.  Take scaffold and place it into 15 ml conical of BBI solution for 25 
minutes 
 
Scaffold in trypsin 
 
_____13.  Place scaffold in 6 ml of trypsin for 6-7 minutes. Agitate and flush lumen 
using pipette. 
_____14.  Deactivate with 6 ml of fibroblast media 
_____15.  Flush lumen to get all cells out 
_____16.  Remove scaffold and dispose  
_____17.  Spin down at 1000 rpm for 5 min 
_____18.  Aspirate the supernatant and re-suspend the cell pellet in 0.5 mL of 
fibroblast media 
_____19.  Place 150 𝜇l cell solution 50 𝜇l of trypan blue 
_____20.  Place 20 𝜇l into cellometer slide and view  
 
Imaging 
 
_____21.  BBI: Turret position 4, FW1 position 1, FW2 position 1 
_____22.  Trypan blue: follow cellometer directions in 209a.  
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Cell Viability Protocol Invitrogen Assay 
 
Prior to bioreactor take down 
_____1. Prepare a Live/Dead stain solution with a Calcein AM 
concentration of 1.0 uM and an EthD-1 concentration of 2.0 uM in DCF-
PBS (approximately 7 ml of staining solution will be needed for each 
scaffold).  
a. The following dilution will result in a 1.0 uM Calcein AM and 2.0 
uM EthD-1 solution with a total volume of 20 ml when using the 
Live/Dead Viability/Cytotoxicity Kit (Invitrogen, L-3224).  
i. Stock solution: 20 mL of DCF-PBS, 20𝜇l of EthD-1, 5𝜇L 
Calcein AM. 
_____2. Transfer 7mL of the staining solution into a 15 mL foil wrapped 
conical tube for each scaffold being assessed. Store conical in fridge 
before use.  
During bioreactor take down 
_____3. Transfer PLGA scaffold into 7 mL of trypsin for 6-7 minutes. Be 
sure to agitate the conical several times to remove cells from the inner 
lumen of the scaffold.  
_____4. After sitting in trypsin, deactivate with 7 mL of culture media. Be 
sure to flush lumen with culture media to fully remove cells from inner 
lumen.  
_____5. Dispose of the scaffold in the biohazard bin and spin down 14 mL 
cell suspension at 1000 RPM for 5 minutes.  
_____6. Aspirate the supernatant and resuspend the cell pellet in 5 mL of 
the Live/Dead staining solution.  
_____7. Let the scaffold sit in the staining solution for 30 minutes at room 
temperature.  
_____8. After 30 minutes transfer two 10 𝜇L samples of the suspension to 
Grids A and B in a disposable hemocytometer.  
_____9. Image both grids at 40X magnification using the fluorescent 
microscope in 192-106B.  
a. Live cell images: use FW1 position 2, FW2 position 2. 
b. Dead cell images: use FW1 position 2, FW2 position 3.  
c. Use brightfield to capture hemocytometer grid.  
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Cell Viability Rhodamine Protocol  
 
_____1. Take bioreactor out of incubator 
_____2. Be sure CO2 tank is off 
_____3. Place in sink and drain transmural fluid  
_____4. Unscrew scaffold from end caps and remove scaffold from bioreactor 
_____5. Transfer scaffold into 7 mL of formalin for 15 minutes. 
_____6. Extract scaffold from formalin and remove from barbs.  
_____7. Cut scaffold in half longitudinally. 
_____8. Wash in PBS twice. 
_____9. Permealize in .1% tritonX-100 (.2 ml of triton in 1.8 in PBS) (in the fridge 
in the “PECAM” Tupperware) for 5 minutes. 
_____10.  Wash in PBS twice 
_____11.  Stain with Rhodamine (in the freezer, wrapped in foil) for 20 minutes. For 
dilution 20ul of stock into 800 𝜇l of PBS. 
_____12.  Wash with PBS.  
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Appendix E – Small-Scale Barbs 
 
 To further create a robust model of the BBB, introducing more 
physiological components is important to further validate the system. To progress 
further toward that notion, two students, Matt Rogers and Nathan Ferrier, 
developed small-scale barb fittings that allowed the use of 1mm inner diameter 
scaffolds. Previously, the bioreactor system utilized 2mm inner diameter Qosina 
barb fittings that were donated for this project. With the creation of these smaller 
scale barb fittings, cellular interaction as well as further development of a BBB 
can be achieved. The fittings were made to improve upon the previous Qosina 
barb fittings  used to secure the scaffolds. The design requirements were to have a 
fitting that would be compatible with sterilization techniques used in the lab, 
ability to produce flow, and allow the use of smaller diameter scaffolds. The 
material chosen was 316-stainless-steel. This allowed compatibility to both 
sterilization techniques including EtO and autoclave. The fitting was designed to 
be a hex shape to provide sufficient installation into the scaffold cap. The fitting 
was able to allow flow through its inner lumen. A barb was machined at the end 
to allow sutures to wrap around the fitting to secure scaffolds. Cellular testing 
conducted with the small-scale barb fittings were not included in this thesis, 
however these tests can provide experiments for future testing in the laboratory. 
Cellular testing can evaluate cell distribution with the use of these barb fittings, 
and further assess if cell distribution is better compared to the protocols under the 
use of the Qosina barbs. If the small-scale barbs do not show improved results, 
changes to protocols must be made to achieve better distribution of cells.  
